Full Text

Turn on search term navigation

1. Introduction

Acorus tatarinowii Schott. (A. tatarinowii) is a common perennial herbaceous plant [1]. It is mainly distributed from northern temperate to subtropical regions, especially in China, Japan, India, Thailand, and Korea [2]. A. tatarinowii is one of the most widely distributed and frequently used natural medicinal plants from the genus Acorus and has a long documented history of medicinal use in the empirical medical system. A. tatarinowii first appeared as a traditional Chinese medicine (TCM) in the earliest Chinese medicinal classic work Shennong’s Classic of Materia Medica (written more than 2000 years ago during the Han Dynasty). It is widely used in folk medicine for treating complex and difficult ailments as well as some serious diseases and has achieved remarkable therapeutic effects. It was included for the first time in the 1963 edition of the Pharmacopoeia of the People’s Republic of China [3] as a TCM in clinical use and was continuously included until the latest 2020 edition [4]. Dried rhizomes are the main A. tatarinowii medicinal parts, and these have been commonly used alone or combined with other TCM in China to treat stroke, dementia, depression, seizure, and mental disorders for centuries [5]. Many Chinese medicinal formulae containing A. tatarinowii have been widely used in clinical practice. At the same time, many commercial Chinese patented medicinal products containing A. tatarinowii are circulating in the market to treat specific diseases. Moreover, certain active ingredients are extracted from A. tatarinowii as pharmaceutical raw materials [6]. As a medicinal plant, A. tatarinowii has significantly contributed to people’s health and the traditional medical systems.

Over the past few decades, A. tatarinowii has attracted increasing interest as an important medicinal plant from both researchers in natural medicine and pharmaceutical institutions. Significant progress in the isolation and identification of A. tatarinowii active constituents has been made. A. tatarinowii contains many phytochemical components with diverse structures and different activities. Thus far, more than 160 components have been identified and characterized. They mainly include phenylpropanoids, terpenoids, lignans, flavonoids, alkaloids, amides, organic acids, and others. Modern pharmacological studies have shown that these chemical components have potent properties, such as antidepressant, antiepileptic, anticonvulsant, antianxiety, antifatigue, and antifungal properties, and they have been shown to improve Alzheimer’s disease (AD) [7,8]. It is worth noting that A. tatarinowii has shown potent neuroprotective effects. A. tatarinowii can reduce brain nerve injury by regulating neurotransmitter levels and improving blood circulation in the brain. It offers good protection for the brain’s nervous system. Whether used alone or as a prescription, A. tatarinowii is an important and indispensable herb to treat depression and is used in the TCM treatment system [9]. However, some clinical observations have shown that the active ingredients of A. tatarinowii have potential toxicity. Therefore, it is necessary to be cautious in using A. tatarinowii as a treatment method, strictly control the dose of A. tatarinowii, and better protect people’s health [10]. If it is disturbed and stimulated by the external environment, it will aggravate the poisoning condition. Therefore, safety measures and comprehensive research should be carried out in the future [11,12]. The exploitation and TCM applications in the prevention and treatment of various diseases are gradually growing due to the in-depth study of TCM. Thus, research on A. tatarinowii is becoming increasingly necessary [13].

Research on A. tatarinowii has advanced significantly due to recent international growth in TCM recognition and contemporary scientific and technical advancements. Reviewing the existing and available literature, it was found that although a large number of studies have been carried out on A. tatarinowii, they mainly focus on a single aspect of its phytochemistry or pharmacology. However, there is still a lack of a comprehensive review specifically for A. tatarinowii. Therefore, it is very important and necessary to conduct a comprehensive review of the research progress on A. tatarinowii in recent years. This is the first up-to-date review of A. tatarinowii research developments which includes its botany, traditional uses, phytochemistry, and pharmacology. It offers a review of A. tatarinowii research, points out gaps in existing research, and suggests new areas for investigation. The authors hope this review will inspire new research on the pharmacological effects and processes behind A. tatarinowii therapeutic effects and provide researchers with a wider perspective and fresh ideas for studying the plant’s present and prospective uses.

2. Botany

A. tatarinowii is a semi-evergreen perennial hairless plant. It usually grows in creeks, ponds, and other humid environments below 2600 m. According to the online records of China’s flora (http://www.cn-flora.ac.cn/index.html accessed on 15 March 2023), it has a creeping rhizome. The rhizome is aromatic, with a thickness of 2–5 mm, externally light brown, and its internode length is 3–5 mm, with mostly fibrous roots. The rhizome’s upper part is very dense, and branches are often fibrous, persisting at the leaf base. Leaves are sessile with a thin leaf blade, with membranous leaf sheaths up to 5 mm wide on both sides of the base, ascending to the middle of the leaf blade, tapering, and undergoing abscission. The leaf blade is dark green, linear, 20–30 cm long, and its base is folded in half and spread above the middle. It is 7–13 mm wide, with a tapering apex, no middle rib, many parallel veins, and a slightly raised angle. It has an axillary inflorescence stalk, 4–15 cm long, that is triangular. The bracts are 13–25 cm long, the fleshy spikes are 2–5 times longer, and are subequal in length. The inflorescences are terete, 4–6.5 cm long, 4–7 mm thick, superficially acuminate, erect, or slightly curved. The flowers are white. The mature fruit is 7–8 cm long and up to 1 cm thick. The young fruits are green, yellow-green, or yellow-white when mature. The flowering period is from February to June. Usually, rhizomes are dug out in autumn and winter, and leaves and fibrous roots are removed, cleaned, and further dried to obtain the medicinal part of A. tatarinowii. The A. tatarinowii herbal parts used in Chinese medicine are usually flat or long and thick. The plant’s features are shown in Figure 1. The outer skin is gray-brown, with some visible links and root marks. The cut surface is fibrous, white, or reddish, with distinct rings and oil spots. It has a sweet odor and a bitter, pungent taste. The observation of some sections of A. tatarinowii under the microscope showed that the outer wall of epidermal cells on the transverse section of the A. tatarinowii rhizome was thickened and brown, and some also contained reddish-brown substances. The cortex of A. tatarinowii is wide, with scattered fiber bundles and leaf trace vascular bundles. The leaf trace vascular bundle is externally hardened, and the vascular bundle sheath fibers are ringed and lignified; the endodermis is clearly visible. The vascular bundle of the middle column is of the wood type and outer type, and the vascular bundle sheath fiber is less. The cells around the fiber bundles and vascular bundle sheath fibers contain calcium oxalate crystals, forming crystalline fibers. Round-like oil cells are scattered in parenchyma cells that contain starch granules.

3. Traditional Uses

A. tatarinowii has been widely used as a medicinal plant in China for 2000 years. Since ancient times, researchers have continuously explored and exploited TCM practices. TCM uses in the treatment and prevention of disease have boosted trust and resolve in its advancement and innovation. In the recorded history of folk culture, A. tatarinowii is a commonly used TCM. Generally speaking, each TCM has its inherent taste and characteristics. A. tatarinowii has a bitter and spicy taste and a warm nature. In addition, according to the different meridians of each TCM, A. tatarinowii has a stimulating effect on the heart and stomach meridians. Based on its action on these meridians, it can calm the mind, resolve dampness, harmonize the stomach, and unblock painful obstructions. It releases the exterior while dispersing cold and expelling wind-dampness. The property of sexual taste meridian attribution is very important in guiding clinical drug applications in the TCM system [14]. It is used for multiple medicinal purposes, traditionally for treating epilepsy, depression, fever, dizziness after a high fever, deafness, heartache, stomachache, and other diseases. A. tatarinowii has a long medicinal use history in China, and it is not only an important TCM itself but is also a critical part of TCM prescriptions [15,16,17,18,19]. In addition to using A. tatarinowii to treat different diseases, A. tatarinowii can be combined with different TCMs to achieve improved therapeutic effects. For example, A. tatarinowii is commonly used with TCMs such as bupleurum and turmeric, which have significant antidepressant effects, to prepare a mixed formulation to improve its antidepressant effect. It is commonly used in depression-like disorders in the clinical environment [20,21]. Further, preclinical studies have shown that A. tatarinowii has strong antidepressant activity. Many studies have found that its water extract, ethanol extract, and extract with other solvents have strong activity from the perspective of different extraction methods. Further studies have shown that the active ingredient asarone exhibits a strong antidepressant effect and is of great research value [9]. In addition to this, the A. tatarinowii ethanol extract has antifungal activity and can be used to treat digestive diseases, such as diarrhea [1]. In addition, in Korean medicine, after a lot of verification, it has also been found that A. tatarinowii has a positive therapeutic effect on brain diseases such as meningitis and is also effective for AD, Parkinson’s disease (PD), and other neurological diseases caused by population aging. In addition, the process of A. tatarinowii treating brain diseases and nervous system diseases has been found to be the same as in our cognition of the TCM system [22,23,24]. In short, the various therapeutic effects of A. tatarinowii in traditional uses, as well as its potential for future applications, have been supported by abundant evidence and warrant further investigation.

4. Phytochemistry

To date, A. tatarinowii has been investigated from a phytochemical perspective. The literature indicates the presence of numerous chemical compounds, such as phenylpropanoids, terpenoids, lignans, flavonoids, alkaloids, amides, organic acids, and other classes. Until now, more than 160 compounds have been isolated and characterized. These compounds are summarized in Table 1.

4.1. Phenylpropanoids

Phenylpropanoids are a class of natural compounds that contain one or several C6-C3 units in their structure. Phenylpropanoids isolated from A. tatarinowii often have a specific characteristic structure, bearing methoxy groups in the benzene ring. Till now, 35 phenylpropanoids (1–35) have been isolated from the rhizomes of A. tatarinowii (Figure 2). Among the phenylpropanoids, α-asarone and β-asarone were reported to be the major A. tatarinowii constituents.

4.2. Sesquiterpenes

At present, more than 20 sesquiterpenoids have been isolated from A. tatarinowii. Sesquiterpenes are the most abundant group of terpenoids, whose skeleton is composed of 3 isoprene units and contains 15 carbon atoms. The oxygenated derivatives of sesquiterpenes have a strong aroma and biological activity and are also important raw materials in the medicine, food, and cosmetics industries. Most sesquiterpenes in A. tatarinowii are monocyclic sesquiterpenes (Figure 3).

4.3. Lignans

Lignans are a class of natural compounds that result from the polymerization of two molecules (a few are from three or four molecules) of phenylpropanoid derivatives, and they are mainly present in the wood and resin of plants. The lignan monomers are mainly composed of cinnamic acid, cinnamyl alcohol, propenyl benzene, and allyl benzene [44]. At present, more than 40 lignans have been extracted from A. tatarinowii, mainly divided into two structural types: monoepoxide lignans and double epoxide lignans. Among them, Veraguensin (65), Magnosalicin (66), (2S,3R)-ceplignan (71), (2R,3S)-ceplignan (72), Acortatarinowin I (75), Acortatarinowin J (76), Acortatarinowin K (77), Acortatarinowin L (78), Saucernetindiol (82), Machilin-I (83), and others are monoepoxide lignans, while Tatarinowin (62), Eudesmin (67), (±)-Acortatarinowin F (90), and (±)-Pinoresinol (106) are double epoxide lignans (Figure 4).

4.4. Flavonoids

Flavonoids are a class of compounds with a core nucleus of a 2-phenyl chromone molecule and no oxygen-containing group substitution at the 3-position. They are widely present in the plant kingdom and are among the most active natural active ingredients [45]. Three flavonoid glycosides have been isolated from rhizomes of A. tatarinowii: Kaempferol-3-O-rutinoside (107), Rhoifolin (108), and Isoschaftoside (109). Compared with other compounds, there is not a lot of information on A. tatarinowii flavonoid structure. Therefore, future efforts should be made to isolate and characterize flavonoids in A. tatarinowii. The chemical structures of the flavonoid compounds are shown in Figure 5.

4.5. Alkaloids

Alkaloids are secondary metabolites that contain nitrogen atoms in the negative oxidation state and are present in biological organisms. They are alkaline organic compounds containing nitrogen. Alkaloids are also important plant chemical constituents known to have various pharmacological effects in humans and animals. To date, seven alkaloids (110–116) have been isolated from A. tatarinowii (Figure 5).

4.6. Amides

Acyl compounds linked to nitrogen atoms are termed amides, a class of nitrogen-containing carboxylic acid derivatives. The amide bond is the most typical functional group in chemical, biological, and pharmaceutical compound synthesis. Because of the importance of amide bonds, their synthesis has become the most commonly used reaction in drug synthesis. Over 11 amides have been discovered in A. tatarinowii (117–127), which are derived from a straight chain amide with an isobutyl group (Figure 6).

4.7. Organic Acids

Organic acids are a class of compounds containing carboxyl groups and are abundant in the leaves, roots, and especially fruits of plants. Most of them are present in the form of salt, and some of them are combined into esters. Thirteen organic acids were isolated from A. tatarinowii, of which 128–132 were aromatic organic acids. Most organic acids isolated from A. tatarinowii exhibit weak acidity (Figure 7).

4.8. Others

In addition to the compound classes mentioned above, more than 20 other compounds have been isolated from A. tatarinowii, including the diterpenoids Tatarol (142) and Tataroside (143), the phenolic compounds Aspidinol (148) and Apocynin (149), the esters 3-butyl-phthalide (152) and diisocaprylphthalate (163), the ether polymer Bisasaricin (156), and others (Figure 8). The above findings illustrate the wide chemical composition of A. tatarinowii, which is of immense future research value.

5. Pharmacological Activities

Modern pharmacological research has revealed that A. tatarinowii exerts various pharmacological activities, including antidepressant, antiepileptic, anticonvulsant, antianxiety, neuroprotective, antifatigue, antifungal, improving AD, and others. These increasingly in-depth pharmacological studies provide an improved scientific basis for clinical practice (Figure 9). The properties of A. tatarinowii active compounds, their pharmacological effects, and potential mechanisms of action on the basis of different types of extracts and compounds are summarized in Table 2.

5.1. Antidepressant Properties

Depression, under the increasing pressure of social activities, has gradually become one of the most common psychiatric disorders. It severely limits psychosocial functioning and quality of life. At the same time, it is becoming a heavy economic burden to society and families [6,56]. Studies have shown that the water extract of A. tatarinowii can be effective against depression. Experiments were carried out using the forced swimming test (FST), tail suspension test (TST), and locomotor activity (LA) in mice. The mice were acclimated in a quiet laboratory for 60 min and then placed in water alone for 6 min. The mice were suspended from the tail end with tape at about 2 cm from the tail tip so that the mice were suspended 15 cm from the ground. Their movement within the next 30 min was recorded using a high-definition digital camera. The immobility time of mice in the above conditions was recorded. The results confirmed that the A. tatarinowii water extracts significantly decreased mice immobility time but did not alter the mice’s locomotor activity. At the same time, the serotonin transporter (SERT) activity was significantly increased at a dose of 100 μg/mL of the A. tatarinowii water extract. Moreover, the petroleum ether extract of A. tatarinowii also significantly increased SERT activity at a dose of 1.56 μg/mL. In contrast, the water extract after petroleum ether processing significantly inhibited SERT activity at 50–100 μg/mL. Thus, A. tatarinowii could regulate SERT activities in a bidirectional manner, potentially exerting its antidepressant properties [9]. In addition, α-asarone and β-asarone, the main components of essential oil (EO) from the rhizome of A. tatarinowii, were found to exhibit antidepressant effects. The same experiment was carried out in mice, showing that at a 5, 10, and 20 mg/kg dose of α-asarone and β-asarone, the immobility time of mice was significantly reduced (p > 0.01). The antidepressant, imipramine, was the positive control at a dose of 15 mg/kg. Notably, α-asarone significantly reduced the immobility time at doses of 10 and 20 mg/kg (p > 0.05 and p > 0.01) compared with the control. Furthermore, the immobility time was also decreased by β-asarone at a dose of 20 mg/kg (p > 0.05). The mean immobility times after α-asarone and β-asarone administration were as follows: α-asarone (5, 10, and 20 mg/kg) 205.1 ± 19, 178 ± 15, and 159 ± 17 s, β-asarone (5, 10, and 20 mg/kg) 223 ± 23, 198 ± 18, and 179 ± 18 s. These results indicate dose-dependent antidepressive-like activities of α-asarone and β-asarone [46].

In addition, to evaluate the influence of the A. tatarinowii β-asarone on depressive-like behavior induced by the chronic unpredictable mild stress (CUMS) model, the CUMS rat model of depression was used. During 28 straight days at a volume of 0.01 g/mL, β-asarone (25 mg/kg/day) or an equivalent amount of saline served as the control for rats exposed to CUMS. When compared to CUMS-exposed rats, the time spent motionless was considerably decreased by 29% after being administered β-asarone (p < 0.05). Moreover, the Sucrose Preference Test (SPT) revealed that sucrose preference was 45% lower in CUMS-exposed rats as compared with non-stressed control rats. Additionally, β-asarone in A. tatarinowii was shown to promote hippocampal neuronal neurogenesis in CUMS-exposed rats, significantly increasing the CREB and BDNF mRNA levels. Furthermore, this research also showed that adult neurogenesis plays a role in the antidepressant-like behavioral outcomes of β-asarone, indicating that β-asarone from A. tatarinowii is a prospective option for the treatment of depression [47]. In conclusion, A. tatarinowii extracts can have a potent antidepressant effect, providing an important natural medicine option for treating depression.

5.2. Antiepileptic Properties

Epilepsy is a neurological disease caused by abnormal neuron discharge in the brain. Its onset often leads to temporary brain dysfunction, accompanied by fainting, convulsions, and other pathological reactions, affecting the normal life of many patients [57,58]. Studies have shown that A. tatarinowii extract has antiepileptic effects [59]. The maximal electroshock (MES), pentylenetetrazol (PTZ) maximal seizure, and prolonged PTZ kindling models were used to test the extract’s antiepileptic properties. Mice with persistent convulsions with tonic hindlimb extension were randomly divided into different groups. Electric stimulation was given 45 min after intraperitoneal administration of the drug or normal saline (NS), and each group’s convulsive rate was recorded. PTZ at 100 mg/kg was injected intraperitoneally 45 min after the drug or NS administration. Convulsive and mortality rates, as well as seizure latency, were recorded. The results indicated that both the decoction (at a dose of 10–20 g/kg) and volatile oil (at 1.25 g/kg) of A. tatarinowii significantly decreased the epileptic rate in the MES model. The A. tatarinowii decoction was effective in the PTZ model, with decreased epileptic and mortality rates. In the dosage range studied, the A. tatarinowii volatile oil was unable to prevent seizures, although a dose of 1.25 g/kg was observed to lengthen seizure latency and reduce mortality. The long-term PTZ kindling model was established in male Sprague Dawley (SD) rats. In the PTZ kindling model, γ—aminobutyric acid (GABA) immunohistochemical reaction (IR) (GABA-IR) neurons decreased significantly compared with the normal group. After therapy with the decoction and volatile oil, the severity of the seizures dramatically diminished in the treated groups. As compared to PTZ kindling controls, more GABA-IR neurons were discovered. Morphological examination also indicated that GABA-IR neuron loss was less severe in the drug-treated groups. All in all, both the decoction and volatile oil extracted from A. tatarinowii were shown to possess antiepileptic properties. The volatile oil was less effective for PTZ-induced epilepsies. Both extracts could prevent epileptic episodes, as well as epilepsy-related GABAergic neuron damage in the brain in the prolonged PTZ kindling model [48,60,61]. These results provide a scientific basis for the clinical antiepileptic application of A. tatarinowii and benefit the development and production of novel antiepileptic drugs.

5.3. Anticonvulsant Properties

The typical clinical manifestations of convulsive seizures are sudden loss of consciousness and sudden generalized or localized, tonic or clonic facial and limb muscle convulsions. Prolonged convulsions can cause hyperthermia, hypoxic brain damage, cerebral edema, and even cerebral hernia, which can be life-threatening [62,63]. A. tatarinowii lignans, especially eudesmin, have shown significant anticonvulsant effects on mice. MES- and PTZ-induced seizures in male mice were used to evaluate the anticonvulsant activities of eudesmin. Mice were pretreated with intraperitoneal injections of eudesmin (5, 10, and 20 mg/kg), while NS (20 kg/mL) was used as the blank control group. Mice from the MES model group were intraperitoneally injected with phenytoin (20 mg/kg) again, while the PTZ model group was injected with diazepam (4 mg/kg). After 30 min, the MES model group was given an electric shock, and the PTZ model group was subcutaneously injected with PTZ (90 mg/kg). The results showed that eudesmin exhibited significant anticonvulsant effects at the 5, 10, and 20 mg/kg doses. In addition, no convulsion or death was observed in the mice treated with the positive control drugs phenytoin 20 mg/kg and diazepam 4 mg/kg. Finally, the eudesmin mechanism of action was investigated by determining the glutamic acid (Glu) and gamma-aminobutyric acid (GABA) content in epileptic mice and glutamate decarboxylase 65 (GAD65), GABAA, Bcl-2, and caspase-3 gene expression in the brain of chronic epileptic rats. The MES and PTZ test results revealed that eudesmin isolated from A. tatarinowii possesses significant anticonvulsant effects. Furthermore, after eudesmin treatment, the GABA content increased, whereas the Glu content decreased, and the ratio of Glu/GABA decreased. Moreover, GAD65, GABAA, and Bcl-2 were up-regulated after treatment with eudesmin, whereas caspase-3 was down-regulated. In summary, the anticonvulsant effect of eudesmin isolated from A. tatarinowii may be associated with the up-regulation of GABAA and GAD65 expression and neuron anti-apoptosis in the brain [49,64]. Another study found that the anticonvulsant effect against the pain models in mice was observed when an A. tatarinowii methanol extract was administered orally at 100 and 200 mg/kg doses. The anticonvulsant effect was studied through the PTZ-induced seizures method. The results suggest that the activity of GABA might potentiate the anticonvulsant effects [50]. In summary, these findings may provide novel directions or insights into treating convulsions using TCM, such as A. tatarinowii.

5.4. Antianxiety Properties

One of the most prevalent mental diseases and the primary contributor to psychosocial dysfunction is anxiety. This disorder causes high costs in terms of healthcare use, disability, loss of productivity, and patient quality of life [65]. A frequent comorbidity of chronic pain is anxiety illness. Those who experience chronic pain are more likely to develop anxiety problems, according to earlier research. Tian et al. discovered that A. tatarinowii extract has potential antianxiety properties. Previous studies have shown that anxiety-like behavior could be induced in mice with persistent inflammatory pain. First, to induce chronic inflammatory pain, a single dose of complete Freund’s adjuvant (CFA) (50% of 10 μL CFA) was injected into the plantar surface of the left hind paw. Mice exhibited significant anxiety-like behavior two weeks after the CFA injection [66]. The mice were placed in a central square device, allowing free movement for 5 min. The number of entries and time spent in each treatment arm were recorded. Mice were placed in the box’s center and allowed to explore freely for 15 min. A decrease in the time spent and the number of entries in the open arms in the elevated plus maze test (EPMT) revealed the anxiety-related behavioral phenotype as well as a decrease in the percentage of time spent in central areas in the open field test (OFT). Administration of α-asarone (2 and 20 mg/kg) for one week (from day 8 to day 14 after CFA injection) inhibited the anxiety-like behavior in a dose-dependent manner without affecting locomotor activity. This was achieved by regulating the balance between GABAergic and glutamatergic transmission in the basolateral (BLA), achieving partially inhibited chronic pain-induced anxiety-like behaviors in mice [51,67]. On the other hand, it has been suggested that GABAergic inhibition is essential for the modulation and maintenance of excitation/inhibition balance. GABAA receptors play the most important role in GABAergic inhibition. Clinically, some anxiolytic drugs exert their effects by binding with the GABAA receptors [68,69]. The above investigations will serve as a guide for more in-depth clinical uses of A. tatarinowii for the treatment of anxiety.

5.5. Neuroprotective Properties

At present, there are many protective mechanisms for neurological disorders, and oxidative stress in the neuronal cell has been proposed to play a crucial role in disease progression [70]. The use of A. tatarinowii and its primary components, α-asarone and β-asarone, in treating neurological illnesses, particularly in neuroprotection, has been supported by a number of lines of evidence [71,72,73,74]. Test-butyl hydroperoxide (tBHP)-induced rat primary astrocytes were used to evaluate the neuroprotective properties of the volatile oil and asarone from A. tatarinowii. Primary cultured rat astrocytes were plated and pretreated with different medications for 48 h. Then, the cultures were treated with tBHP for 3 h. Cultured rat astrocytes were pretreated with α-asarone, β-asarone, or the A. tatarinowii volatile oil for 48 h. The A. tatarinowii representative constituents exhibited promising protective effects on the cultures. The administration of tBHP in the cultures led to the induction of oxidative stress and cell death, with the application of tBHP considerably lowering cell viability in a dose-dependent manner. The application of these A. tatarinowii representative constituents protected against cell death induced by the tBHP challenge. The tBHP-induced cell death in the cultured astrocytes was considerably decreased after a dose-dependent pretreatment. The A. tatarinowii representative constituents did not show cytotoxicity nor a proliferating effect on the cultures in all the concentrations (0.5 to 15 μg/mL) applied. In addition, α-asarone and β-asarone (3, 10, and 30 mg/kg) have demonstrated antioxidant effects in several animal seizure models [75,76]. They perform a crucial protective function in maintaining normal levels of superoxide dismutase, lipid peroxidation, catalase, and glutathione-peroxidase in various stressed-out areas of rat brains. This suggests that they play a neuroprotective role through an antioxidant pathway [52,77].

Moreover, the β-asarone of A. tatarinowii exhibited neuroprotective effects against spatial memory impairment and synaptogenesis in the chronic lead (Pb)-exposed rats. Both SD developmental rat pups and adult rats were used in the study. Rat pups were exposed to Pb throughout the lactation period, and β-asarone (10 and 40 mg/kg) was given intraperitoneally from postnatal day 14 to 21. In addition, the adult rats were exposed to Pb from the embryo stage to 11 weeks old, and β-asarone (2.5, 10, and 40 mg/kg) was given during the period from 9 to 11 weeks old. The Morris water maze test and Golgi–Cox staining method were used to assess spatial memory ability and synaptogenesis. Rats were anesthetized with CO₂ and quickly decapitated. The brains were longitudinally cut into two halves. One hemisphere was processed for morphological staining, and the other hemisphere was used to examine specific protein expression. It should be noted that A. tatarinowii constituents can pass through the blood–brain barrier quickly [78,79]. It effectively attenuated the Pb-induced reduction of spine density in hippocampal CA1 and dentate gyrus areas in a dose-dependent manner both in developmental and adult rats. At the same time, the Pb-induced impairments of learning and memory were partially rescued. In addition, it resulted in the up-regulation of NR2B, Arc, and Wnt7a protein expression, as well as an increase in the mRNA levels of Arc/Arg3.1 and Wnt7a [12]. In conclusion, the neuroprotective properties of A. tatarinowii offer an intriguing treatment strategy for a variety of neurological disorders.

5.6. Protective Effects against Alzheimer’s Disease

AD is a degenerative disease of the central nervous system primarily characterized by the progressive loss of cognition and memory. AD has several pathological hallmarks, including extracellular amyloid plaque formation, intracellular neurofibrillary tangles, and neuronal loss [80,81,82]. The most important feature of AD is the gradual, irreversible cognitive ability loss through amyloid β (Aβ) plaque formation and of neurofibrillary tangles composed of tau protein [83]. Previous studies have shown that this TCM has ameliorative and protective properties against neurodegenerative diseases, such as Parkinson’s disease and AD, hypoxic–ischemic encephalopathy, and cerebrovascular diseases [84].

β-asarone, the main A. tatarinowii constituent, plays an important role in the central nervous system. Wang et al. established the AD cell model, culturing PC12 cells in vitro, and Aβ_1–42 was then added into the medium at different concentrations and time points. As the concentration of Aβ_1–42 and time increased, the PC12 cell viability decreased in a dose-dependent manner; at the same time, cytotoxicity and LDH increased. Moreover, senescent cells clearly increased in cells treated with Aβ_1–42. After establishing a stable AD cell model, they investigated the effects of gradient concentrations of β-asarone (12, 24, 36, 72, and 144 μM) or donepezil (10, 20, and 40 μM). The β-asarone protective effect on cell proliferation was dose-dependent; the low-dose group demonstrated a better protective effect than the high-dose group. Subsequently, 24, 36, and 72 μM of β-asarone and 9.6 μM of donepezil were chosen as the ideal concentrations, respectively. Compared with model cells, β-asarone and donepezil both improved cell proliferation and decreased cell damage [85,86]. At the same time, they also decreased the cell senescence rate. In conclusion, the study demonstrated that the β-asarone in A. tatarinowii can inhibit Aβ, which has a significant therapeutic effect against toxic protein deposition [54,87].

Another study used adult male Wistar rats to examine the effects of β-asarone on neurodegeneration brought on by intrahippocampal injection of Aβ. The Alzheimer’s disease model was established, and then the rats were treated with β-asarone (12.5, 25, and 50 mg/kg). Rats were randomly divided into groups and were bilaterally injected with Aβ. Thirty days before Aβ administration, an intragastric tube was used to administer β-asarone for fifty days, every day. Once the rats were sacrificed, the hippocampal homogenate’s oxidative stress parameters, superoxide dismutase (SOD), and glutathione peroxidase (GPX) activity were assessed. The results showed that β-asarone at doses of 25 and 50 mg/kg significantly increased the levels of antioxidant enzymes, including SOD and GPX. Moreover, β-asarone significantly decreased cell loss in the cerebral cortex and hippocampus [55,88,89]. These findings suggest that A. tatarinowii and its active constituent β-asarone have potential therapeutic effects against Alzheimer’s disease, which could be useful for the development of new drugs.

5.7. Antifatigue Properties

Fatigue may be defined as the inability to maintain the expected muscle strength, leading to reduced performance during prolonged exercise. However, the cause is usually not muscle fatigue but an increase in serotonin or 5-hydroxytryptamine (5-HT) concentration in the brain during prolonged exercise [90,91]. A. tatarinowii is an ancient TCM tonic nourishment that can be used as an antifatigue medicine. The influence of A. tatarinowii on endurance exercise was determined by the fatigue time of adult male rats during a treadmill exercise. Rats were injected with A. tatarinowii water extract (1, 10, and 100 mg/kg) two hours before the treadmill exercise. Caffeine was used as the positive control drug. A. tatarinowii prolonged the time to exhaustion by treadmill exercise in a dose-dependent way. Notably, A. tatarinowii at 100 mg/kg was just as effective as caffeine (10 mg/kg) in prolonging the time to exhaustion during the treadmill exercise. By preventing the exercise-induced decrease in 5-HT1B mRNA and protein expression in the dorsal raphe, A. tatarinowii was able to increase exercise endurance. It could also attenuate the exercise-induced increase in 5-HT synthesis, the TPH2 mRNA and protein expression, and other effects. Moreover, the effects of A. tatarinowii were comparable to those of caffeine [56,92]. These findings support the traditional medical application of A. tatarinowii and point to its potential therapeutic value as an antifatigue drug.

5.8. Antifungal Properties

Fungal infections can result in many diseases, including dermatosis with skin infections and fungal enteritis with acute or chronic infections of deep tissues, causing significant morbidity and mortality in susceptible populations. Candida spp. are common opportunistic fungal pathogens, among which Candida albicans is the most common infectious fungal agent [93,94]. C. albicans is a normal human intestinal, oral cavity, and vaginal microflora constituent. It can cause infections ranging from easily treatable superficial infections to life-threatening invasive infections [95,96]. The ethanol extract of A. tatarinowii was shown to possess antifungal activities in vivo and in vitro. Its fungicidal efficiency was evaluated in vivo, with mice randomly divided into four groups. In the first group, mice were pricked with a needle in their abdomens and orally fed PBS as the KB-negative control group. The other three groups of mice were infected intraperitoneally with 5 × 10⁵ CFU of log-phase C. albicans. After two days, mice of groups 2–4 were orally fed with the ethanol extract of A. tatarinowii, fluconazole (positive drug control group), or PBS (negative control group) (8 mg/kg) once every day for seven days. After seven days, the ethanol extract of A. tatarinowii significantly reduced the fungal burden in the spleen, liver, and kidney compared to fluconazole. These results suggest that ethanol extract of A. tatarinowii can be used to treat deep C. albicans infections [97]. Additionally, a sterile filter paper disk impregnated with ethanol extract of A. tatarinowii was placed on an agar plate, inoculated with a C. albicans suspension, and incubated under aerobic conditions for 24 h. The diameters of inhibition zones were then measured and recorded. A. tatarinowii resulted in an inhibition zone of 9.9 ± 0.5 mm against C. albicans, compared with 7 mm in the control group. Further, the MIC and MFC values of A. tatarinowii against C. albicans were 51.2 and 102.4 μg/mL. A. tatarinowii showed significantly higher potency against C. albicans than the two positive control drugs, fluconazole and itraconazole, at 51.2 μg/mL [1]. In summary, the ethanol extract of A. tatarinowii has superior antifungal activity in vivo and in vitro [98]. These results could contribute to reducing antibiotic consumption for the treatment of fungal infections, thereby helping to reduce the emergence of antibiotic resistance. They further promote the safe and effective use of A. tatarinowii for traditional and modern medical applications.

6. Conclusions and Perspectives

This review provided the scientific foundation for future research on A. tatarinowii and the development of better therapeutic agents using the natural medicinal plant. At the same time, according to the traditional literature and contemporary evidence, the present research status of A. tatarinowii was critically reviewed. Nowadays, A. tatarinowii is widely used in the treatment of brain diseases and nervous system diseases and has achieved satisfactory therapeutic effects (Figure 10). A. tatarinowii can treat brain diseases, such as epilepsy, anxiety, and depression, by regulating neurotransmitter levels. It can also improve blood circulation in the brain to alleviate neurological diseases, such as AD. To date, over 160 compounds have been isolated and identified from A. tatarinowii. It is expected that more active ingredients will be identified and characterized in future research. On the other hand, pharmacological studies published in the literature with in vitro and in vivo assays largely corroborate its wide medicinal use. These studies indicated that both the extracts and active constituents of A. tatarinowii possess a wide range of pharmacological activities. These modern pharmacological studies supported most traditional uses of A. tatarinowii as an indispensable TCM.

Although significant work has been conducted on A. tatarinowii, some scientific gaps still need to be explored. Firstly, the reported studies have shown that the main chemical components of A. tatarinowii are phenylpropanoids. At the same time, there are relatively few other chemical constituents extracted and isolated from A. tatarinowii. More chemical constituents must be identified to explore the relationship between bioactive constituents and pharmacological effects in depth. More advanced instruments to separate and identify rare compounds in A. tatarinowii should be utilized to study their pharmacological activity. The active components of the aboveground parts of A. tatarinowii, such as stems and leaves, should be studied to contribute to the rational utilization of the plant’s resources and to identify the concentration of active compounds in the different plant tissues. Secondly, the research on the medicinal parts of A. tatarinowii is not comprehensive enough. Due to the highly variable secondary metabolism in plants, the chemical components and pharmacological effects of the different medicinal parts of A. tatarinowii plants are also very different. A. tatarinowii showed good anti-AD properties. Due to the aging society, the morbidity and prevalence rate of senile diseases such as AD and PD are growing at an accelerated pace. Therefore, it is urgent to study a new and novel drug for treating AD. The active ingredients of A. tatarinowii come from different tissues of the plant. Further pharmacological studies should be conducted on different chemical components of rhizomes and/or any other parts of A. tatarinowii to provide a sufficient scientific basis and in-depth research on the function and mechanism of the identified active ingredients. We expect this will be the key direction of future research. Thirdly, systematic data on pharmacokinetics and clinical studies of A. tatarinowii are limited, and there are few studies on target organ toxicity. We should conduct more clinical studies to evaluate possible therapeutic effects and investigate the side effects and toxicity of A. tatarinowii. The toxic effect of asarone in A. tatarinowii may limit its therapeutic effect. Toxicological studies have shown that α-asarone and β-asarone in A. tatarinowii can cause hepatomas, which may have mutagenic, genotoxic, and teratogenic effects. It has been reported that β-asarone is more toxic than α-asarone. In a study involving the human body, several consumers experienced persistent vomiting due to long-term intake of A. tatarinowii containing high concentrations of asarone. In addition, asarone also showed cytotoxic and genotoxic effects on HepG2 cells. Due to the potential toxic effects of asarone, in particular β-asarone, the European Council has limited the content of β-asarone in alcoholic beverages and condiments to 1 mg/kg and in other foods and beverages to 0.1 mg/kg. Based on the existing literature, further dose-dependent in vivo studies are needed to confirm the mutagenicity, genotoxicity, and teratogenicity associated with α-asarone and β-asarone. In addition, it is speculated that the epoxide metabolites of α-asarone and β-asarone may be the cause of these toxicities. Importantly, considering the toxicity of α-asarone and β-asarone, the clinical use of these compounds carries certain risks. On the other hand, other compounds such as sesquiterpene Acorusin E and indole alkaloids in A. tatarinowii have also been reported to have potential toxicity. Studies have shown that high doses of Acorusin E in A. tatarinowii may inhibit the central nervous system. Secondly, long-term or high-dose intake of indole alkaloids in A. tatarinowii may have some adverse effects on the human body, causing nausea, vomiting, dizziness, diarrhea, and other symptoms. In addition, indole alkaloids may also have effects on the cardiovascular system, such as arrhythmia and blood pressure changes [7,99,100]. Therefore, it is necessary to be cautious in determining the human administration regimen of A. tatarinowii to avoid toxicity and protect human health. Further research may focus on the pharmacodynamic material relationship, pharmacokinetics, clinical research, and toxicological evaluation of A. tatarinowii. At the same time, A. tatarinowii has potential as a nutritional supplement that promotes health. As people are increasingly conscious of their well-being, there is a growing demand for edible Chinese medicines that offer health benefits. Thus, further studies should be conducted on A. tatarinowii health products to explore their potential for future development. The premise of in-depth development and utilization of natural plant resources may be evaluating and controlling their quality. However, there are still some shortcomings in the quality control of A. tatarinowii. Nowadays, A. tatarinowii on the market is easy to confuse with Anemone altaica Fisch. Fortunately, they belong to different families of plants or are easy to distinguish. In addition, since the TCM composition and pharmacological effects are usually complex, for their quality control, single components and multiple components may be utilized to assess the quality of a specific TCM, especially the chemical components related to its efficacy. The study of the pharmacodynamic material basis of A. tatarinowii mostly focuses on the study of its volatile components. According to the latest edition of the pharmacopeia (2020), the volatile oil content in the chemical composition of A. tatarinowii should not be less than 1.0% (mL/g), and the volatile oil in the Chinese herbal pieces should not be less than 0.7% (mL/g) [4]. However, the volatile oil components of A. tatarinowii are mixtures and unstable. With further in-depth research on A. tatarinowii, certain unique components of A. tatarinowii, such as phenylpropanoids and lignans, can be selected as its quality markers [101,102]. This will provide a solid foundation for scientifically developing and utilizing more A. tatarinowii plant resources. This will also help to protect people’s health and safety better. Therefore, it is necessary to develop new and effective analytical methods and techniques to identify multiple components to achieve more comprehensive quality control of A. tatarinowii.

In summary, A. tatarinowii is an important medicinal plant and a source of phytochemicals with extensive pharmacological activities and high application value in all respects. However, further comprehensive and in-depth clinical studies are required to determine the safety and availability of A. tatarinowii for clinical utility. Until now, many compounds from A. tatarinowii have been found, but further research needs be conducted to provide a more thorough characterization. In the future, the structure–activity relationship and mechanistic action of isolated compounds should be studied to explore their potency and drug-like properties. The present paper systematically reviews the botany, traditional uses, phytochemistry, and pharmacology of A. tatarinowii. We aimed to provide the groundwork for further research on its mechanism of action and the development of improved therapeutic agents using A. tatarinowii in the future. Furthermore, we hope this review highlights the importance of A. tatarinowii and provides useful directions for the future development of this natural medicinal plant.

Author Contributions

M.W. and H.-X.K. proposed the framework of this paper. H.-P.T., S.W. and J.-Y.L. drafted the manuscript and made the tables. W.-J.H., A.-Q.Y. and Q.-X.B. integrated the structural information and designed the pictures. B.-Y.Y. provided some helpful suggestions in this paper. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors have no conflict of interest regarding the publication of this paper.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Figures and Tables

View Image - Figure 1. Plant morphology of A. tatarinowii. (A) Whole plants, (B) leaves, (C) inflorescences, (D) rhizomes, (E) dry rhizomes, and (F) Chinese herbal pieces.

Figure 1. Plant morphology of A. tatarinowii. (A) Whole plants, (B) leaves, (C) inflorescences, (D) rhizomes, (E) dry rhizomes, and (F) Chinese herbal pieces.

Figure 2. The structures of phenylpropanoids in A. tatarinowii.

Figure 3. The structures of sesquiterpenes in A. tatarinowii.

Figure 4. The structures of lignans in A. tatarinowii.

Figure 5. The structures of flavonoids and alkaloids in A. tatarinowii.

Figure 6. The structures of amides in A. tatarinowii.

Figure 7. The structures of organic acids in A. tatarinowii.

Figure 8. The structures of others compounds in A. tatarinowii.

Figure 9. The pharmacological activities of A. tatarinowii. (“↑” indicates an upward revision; “↓” indicates a downward revision).

Figure 10. Therapeutic effects of A. tatarinowii on brain diseases and nervous system diseases.

Table 1

Chemical compounds isolated from A. tatarinowii.

No.	ChemicalComponent	MolecularFormula	ExtractionSolvent	PlantParts	Reference
Phenylpropanoids
1	Acoramo	C₁₂H₁₆O₄	MeOH	Rhizomes	[25]
2	(Z)-Coniferyl alcohol	C₁₀H₁₂O₃	MeOH	Rhizomes	[25]
3	2,4,5-trimethoxybenzoic acid	C₁₀H₁₂O₅	MeOH	Rhizomes	[25]
4	Tatarinoids B	C₁₂H₁₆O₅	MeOH	Rhizomes	[25]
5	Tatarinoids A	C₁₂H₁₆O₅	MeOH	Rhizomes	[25]
6	3-(3,4,5-trimethoxyphenyl) propan-1-ol	C₁₂H₁₈O₄	MeOH	Rhizomes	[25]
7	Acoramone or isoacoramone	C₁₂H₁₆O₄	MeOH	Rhizomes	[25]
8	Asaronaldehyde	C₁₀H₁₂O₄	MeOH	Rhizomes	[25]
9	Isoacoramone or acoramone	C₁₂H₁₆O₄	MeOH	Rhizomes	[25]
10	1-(2,4,5-trimethoxyphenyl) propan-1,2-dione	C₁₂H₁₄O₅	MeOH	Rhizomes	[25]
11	(E)-3-(2,4,5- trimethoxyphenyl) acrylaldehyde	C₁₂H₁₄O₄	MeOH	Rhizomes	[25]
12	2,4,5-trimethoxyl-2′-butoxy-1,2-phenyl propandiol	C₁₆H₂₆O₅	MeOH	Rhizomes	[25]
13	α-Asarone	C₁₂H₁₆O₃	MeOH	Rhizomes	[25]
14	β-Asarone	C₁₂H₁₆O₃	MeOH	Rhizomes	[25]
15	γ-Asarone	C₁₂H₁₆O₃	MeOH	Rhizomes	[25]
16	1-(4-methoxyphenyl) allyl acetate	C₁₂H₁₄O₃	MeOH	Rhizomes	[25]
17	Cis-methylisoeugenol	C₁₁H₁₄O₂	MeOH	Rhizomes	[26]
18	Elemicin	C₁₂H₁₆O₂	MeOH	Rhizomes	[26]
19	Benzoic acid	C₈H₈O₄	95% EtOH	Rhizomes	[1]
20	(R)-4-hydroxy-3-[1-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propan-2-yl]-5-methoxyben-zoic acid	C₁₈H₂₀O₇	Water	Rhizomes	[27]
21	(R)-1-(1,1-dimethoxypropan-2-yl)-2,4,5-trimethoxybenzene [(−)-R-isoacorphenylpropanoid]	C₁₄H₂₂O₅	60% EtOH	Rhizomes	[28]
22	(S)-1-(1,1-dimethoxypropan-2-yl)-2,4,5-trimethoxybenzene [(+)-S-isoacorphenylpropanoid]	C₁₄H₂₂O₅	60% EtOH	Rhizomes	[28]
23	(7R,8R)-7-methoxy-8-hydroxy-dihydroasarone (ent-acoraminol A)	C₁₃H₂₀O₅	60% EtOH	Rhizomes	[28]
24	(7S,8R)-7-methoxy-8-hydroxydihydroasarone (ent-acoraminol B)	C₁₃H₂₀O₅	60% EtOH	Rhizomes	[28]
25	(7R,8R)-7-ethoxy-8-hydroxydihydroasarone (ent-acoraminol C)	C₁₄H₂₂O₅	60% EtOH	Rhizomes	[28]
26	(7S,8S)-7-ethoxy-8-hydroxydihydroasarone(acoraminol C)	C₁₄H₂₂O₅	60% EtOH	Rhizomes	[28]
27	(7S,8R)-7-ethoxy-8-hydroxy-dihydroasarone (ent-acoraminol D)	C₁₄H₂₂O₅	60% EtOH	Rhizomes	[28]
28	(7R,8S)-7-ethoxy-8-hydroxydihydroasarone (acoraminol D)	C₁₄H₂₂O₅	60% EtOH	Rhizomes	[28]
29	Acoraminol A	C₁₃H₂₀O₅	60% EtOH	Rhizomes	[28]
30	Acoraminol B	C₁₃H₂₀O₅	60% EtOH	Rhizomes	[28]
31	(7R,8R)-7,8-dihydroxydihydroa-sarone	C₁₂H₁₈O₅	60% EtOH	Rhizomes	[28]
32	(7S,8R)-7,8-dihydroxydihydroa-sarone	C₁₂H₁₈O₅	60% EtOH	Rhizomes	[28]
33	1-hydroxy-1-(2,4,5-trimethoxyphenyl)propan-2-one	C₁₂H₁₆O₅	60% EtOH	Rhizomes	[28]
34	1-(2,4,5-trimethoxyphenyl)ethanone	C₁₁H₁₄O₄	60% EtOH	Rhizomes	[28]
35	Asaraldehyde	C₁₀H₁₂O₄	60% EtOH	Rhizomes	[28]
Sesquiterpenes
36	2-oxocadinan-1(10),3-dien-5-ol	C₁₅H₂₂O₂	Water	Rhizomes	[29]
37	Isocalamediol	C₁₅H₂₆O₂	Water	Rhizomes	[29]
38	2-hydroxyacorenone	C₁₅H₂₄O₂	Water	Rhizomes	[29]
39	2-acetoxyacorenone	C₁₇H₂₆O₃	Water	Rhizomes	[29]
40	4a,10a-aroma-dendranediol	C₁₅H₂₆O₂	Water	Rhizomes	[29]
41	6,7,8-trihydroxy-4a-isobutyl-4,7-dimethylhexahydro-6,8a-epoxychromen-2(3H)-one	C₁₅H₂₄O₆	Water	Rhizomes	[27]
42	Acorusin D	C₁₅H₂₂O₂	95% EtOH	Rhizomes	[30]
43	Acorusin E	C₁₅H₂₂O₅	95% EtOH	Rhizomes	[30]
44	Litseachromolaevane A	C₁₅H₂₂O₂	95% EtOH	Rhizomes	[30]
45	1β,7α(H)-cadinane- 4α,6α,10α-triol	C₁₅H₂₈O₃	95% EtOH	Roots	[31]
46	1α,5β-guaiane-10α-O-ethyl- 4β,6β-diol	C₁₇H₃₂O₃	95% EtOH	Rhizomes	[31]
47	6β,7β(H)-cadinane-1α,4α, 10α-triol	C₁₅H₂₈O₃	95% EtOH	Rhizomes	[31]
48	Tatarinowin A	C₁₅H₂₂O₂	Water	Rhizomes	[32]
49	Calamusin A	C₁₅H₂₂O₄	95% EtOH	Rhizomes	[33]
50	Calamusin B	C₁₅H₂₂O₄	95% EtOH	Rhizomes	[33]
51	Calamusin C	C₁₅H₂₀O₄	95% EtOH	Rhizomes	[33]
52	Calamusin D	C₁₅H₂₄O₄	95% EtOH	Rhizomes	[33]
53	Calamusin E	C₁₅H₂₂O₃	95% EtOH	Rhizomes	[33]
54	Calamusin F	C₁₅H₂₂O₃	95% EtOH	Rhizomes	[33]
55	Calamusin G	C₁₅H₂₂O₃	95% EtOH	Rhizomes	[33]
56	Calamusin H	C₁₅H₂₂O₃	95% EtOH	Rhizomes	[33]
57	Calamusin I	C₁₂H₁₈O₃	95% EtOH	Rhizomes	[33]
58	Neo-acorane A	C₁₅H₂₂O₄	95% EtOH	Rhizomes	[34]
Lignans
59	4,7,9,9′-tetrahydroxy-3,3′-dimethoxy-8-O-4′- neolignan	C₂₀H₂₆O₇	MeOH	Rhizomes	[25]
60	(7R,8R)-Virolin	C₂₂H₂₈O₆	MeOH	Rhizomes	[25]
61	Ligraminol D	C₂₁H₂₈O₆	MeOH	Rhizomes	[25]
62	Tatarinowin	C₂₃H₃₀O₈	MeOH	Rhizomes	[25]
63	Ligraminol C	C₂₃H₂₈O₆	MeOH	Rhizomes	[25]
64	Polysphorin	C₂₃H₃₀O₆	MeOH	Rhizomes	[25]
65	Veraguensin	C₂₂H₂₈O₅	MeOH	Rhizomes	[25]
66	Magnosalicin	C₂₄H₃₂O₇	MeOH	Rhizomes	[25]
67	Eudesmin	C₂₂H₂₆O₆	MeOH	Rhizomes	[25]
68	2S-(2,6-dimethoxy-4- propenyl-phenoxy)-1 - (3,4,5-trimethoxy-phenyl)- propane-1-one	C₂₃H₂₈O₇	MeOH	Rhizomes	[25]
69	Diasarone I	C₂₄H₃₂O₆	MeOH	Rhizomes	[25]
70	1,3-dimethoxy-2-[1-methyl-2-(3,4,5-trimethoxyphenyl)- ethoxy]-5-(1- propenyl-1-yl)-benzen	C₂₃H₃₀O₆	MeOH	Rhizomes	[25]
71	(2S,3R)-ceplignan	C₁₈H₂₀O₇	Water	Rhizomes	[27]
72	(2R,3S)-ceplignan	C₁₈H₂₀O₇	Water	Rhizomes	[27]
73	Acortatarinowin G	C₂₄H₃₂O₈	95% EtOH	Rhizomes	[35]
74	Acortatarinowin H	C₂₂H₂₄O₆	95% EtOH	Rhizomes	[35]
75	Acortatarinowin I	C₂₃H₃₀O₆	95% EtOH	Rhizomes	[35]
76	Acortatarinowin J	C₂₃H₂₈O₇	95% EtOH	Rhizomes	[35]
77	Acortatarinowin K	C₂₂H₂₆O₆	95% EtOH	Rhizomes	[35]
78	Acortatarinowin L	C₂₂H₂₈O₆	95% EtOH	Rhizomes	[35]
79	Acortatarinowin M	C₂₂H₂₈O₉	95% EtOH	Rhizomes	[35]
80	Acortatarinowin N	C₂₁H₂₆O₈	95% EtOH	Rhizomes	[35]
81	Tatarinoid C	C₂₁H₂₈O₇	95% EtOH	Rhizomes	[35]
82	Saucernetindiol	C₂₀H₂₄O₅	95% EtOH	Rhizomes	[35]
83	Machilin-I	C₂₀H₂₄O₅	95% EtOH	Rhizomes	[35]
84	Verrucosn	C₂₀H₂₄O₅	95% EtOH	Rhizomes	[35]
85	(±)-Acortatarinowin A	C₂₀H₂₄O₇	95% MeOH	Rhizomes	[36]
86	(±)-Acortatarinowin B	C₂₀H₂₄O₇	95% MeOH	Rhizomes	[36]
87	(±)-Acortatarinowin C	C₂₁H₂₆O₈	95% MeOH	Rhizomes	[36]
88	(±)-Acortatarinowin D	C₂₀H₂₄O₇	95% MeOH	Rhizomes	[36]
89	(±)-Acortatarinowin E	C₂₂H₂₈O₇	95% MeOH	Rhizomes	[36]
90	(±)-Acortatarinowin F	C₂₃H₂₈O₇	95% MeOH	Rhizomes	[36]
91	Tatarinan O	C₃₆H₄₈O₉	95% EtOH	Roots	[37]
92	Tatanan A	C₃₆H₄₈O₉	95% EtOH	Rhizomes	[38]
93	Tatanan B	C₃₅H₄₆O₉	95% EtOH	Rhizomes	[38]
94	Tatanan C	C₃₅H₄₆O₉	95% EtOH	Rhizomes	[38]
95	Tatarinoid D	C₂₂H₂₆O₆	60% EtOH	Rhizomes	[39]
96	Tatarinoid E	C₂₃H₂₈O₇	60% EtOH	Rhizomes	[39]
97	Tatarinoid F	C₂₁H₂₈O₆	60% EtOH	Rhizomes	[39]
98	Tatarinoid G	C₂₂H₂₈O₅	60% EtOH	Rhizomes	[39]
99	Tatarinoid H	C₁₉H₂₂O₇	60% EtOH	Rhizomes	[39]
100	[S,R-(E)]-3,4,5-trimethoxy-[1-[2-methoxy-4-(1-propenyl)phenoxy]ethyl]-benzenemethanol	C₂₂H₂₈O₆	60% EtOH	Rhizomes	[39]
101	Nectandrin A	C₂₁H₂₆O₅	60% EtOH	Rhizomes	[39]
102	(2R,3R)-2-(3,4-dimethoxyphenyl)-2,3-dihydro-7-methoxy-3-methyl-5-(1E)-1-propen-1-yl-benzofuran	C₂₁H₂₄O₄	60% EtOH	Rhizomes	[39]
103	Tatarinan T	C₄₈H₆₄O₁₂	95% EtOH	Roots	[40]
104	3-(3,4-dimethoxyphenyl)propan-1-ol	C₁₁H₁₆O₃	60% EtOH	Rhizomes	[28]
105	(±)-Magnosalicin	C₂₄H₃₂O₇	60% EtOH	Rhizomes	[28]
106	(±)-Pinoresinol	C₂₀H₂₂O₆	60% EtOH	Rhizomes	[28]
Flavonoids
107	Kaempferol-3-O- rutinoside	C₂₇H₃₀O₁₅	MeOH	Rhizomes	[25]
108	Rhoifolin	C₂₇H₃₀O₁₄	MeOH	Rhizomes	[25]
109	Isoschaftoside	C₂₆H₂₈O₁₄	MeOH	Rhizomes	[25]
Alkaloids
110	2-(3′,4′-dihydroxy-1′ -butylenyl)-5-(2″,3″,4″-trihydroxybutyl)-pyrazine	C₁₂H₁₈N₂O₅	Water	Rhizomes	[29]
111	Tatarine A	C₁₇H₁₃NO₃	Water	Rhizomes	[29]
112	4-(2-formyl-5-methoxymethyl pyrrol- 1-yl)butyric acid methyl ester	C₁₂H₁₇NO₄	Water	Rhizomes	[29]
113	Tatarine D	C₁₇H₁₃NO₃	60% EtOH	Rhizomes	[41]
114	Neotatarine	C₁₈H₁₃NO₄	95% EtOH	Rhizomes	[42]
115	Acortatarin A	C₁₂H₁₅NO₅	Water	Rhizomes	[43]
116	Acortatarin B	C₁₂H₁₅NO₆	Water	Rhizomes	[43]
Amides
117	Tatarine C	C₁₅H₂₀N₂O₆	MeOH	Rhizomes	[25]
118	Tataramide A	C₁₇H₁₇NO₄	MeOH	Rhizomes	[25]
119	(S)-N-trans-feruloyloctopamine	C₁₈H₁₉NO₅	MeOH	Rhizomes	[25]
120	N-trans-Feruloyl-tyramine	C₁₈H₁₉NO₄	MeOH	Rhizomes	[25]
121	Tataramide B	C₃₆H₃₆N₂O₈	MeOH	Rhizomes	[25]
122	(E)-methyl 4-[3-(4-hydroxy-3-methoxyphenyl) acrylamido]butanoate	C₁₅H₁₉NO₅	Water	Rhizomes	[27]
123	(Z)-methyl-4-[3-(4-hydroxy-3-methoxyphenyl)acrylamido]butanoate enol isomer	C₁₅H₂₁NO₅	Water	Rhizomes	[27]
124	Acorusin A	C₃₅H₃₃NO₈	95% EtOH	Rhizomes	[30]
125	Grossamide K	C₂₈H₂₉NO₇	95% EtOH	Rhizomes	[30]
126	Tatarine E	C₃₁H₃₃NO₉	60% EtOH	Rhizomes	[41]
127	Cannabisin F	C₃₆H₃₆N₂O₈	60% EtOH	Rhizomes	[41]
Organic acids
128	Ferulic acid	C₁₀H₁₀O₄	Water	Roots and Rhizomes	[9]
129	Trans-Isoferulic acid	C₁₀H₁₀O₄	Water	Roots and Rhizomes	[9]
130	3,4,5-trimethoxycinnamic acid	C₁₂H₁₄O₅	Water	Roots and Rhizomes	[9]
131	3,5-dimethoxy-4-hydroxycinnamic acid	C₁₁H₁₂O₅	Water	Roots and Rhizomes	[9]
132	Trans-4-hydroxycinnamic acid	C₉H₈O₃	Water	Roots and Rhizomes	[9]
133	4-hydroxybenzoic acid	C₇H₆O₃	Water	Roots and Rhizomes	[9]
134	Anisic acid	C₈H₈O₃	Water	Roots and Rhizomes	[9]
135	3-hydroxybenzoic acid	C₇H₆O₃	Water	Roots and Rhizomes	[9]
136	Veratric acid	C₉H₁₀O₄	Water	Roots and Rhizomes	[9]
137	3,4,5-trimethoxybenzoic acid	C₁₀H₁₂O₅	Water	Roots and Rhizomes	[9]
138	Gallic acid	C₇H₆O₅	Water	Roots and Rhizomes	[9]
139	Syringic acid	C₉H₁₀O₅	Water	Roots and Rhizomes	[9]
140	Acoric acid	C₁₅H₂₄O₄	95% EtOH	Rhizomes	[34]
Other types
141	1-cis-propenyl-1S,6R- epoxy-4-methoxy- 2,5-quinone	C₁₀H₁₀O₄	MeOH	Rhizomes	[25]
142	Tatarol	C₂₀H₃₄O₇	MeOH	Rhizomes	[25]
143	Tataroside	C₂₆H₄₄O₁₂	MeOH	Rhizomes	[25]
144	Isocalamediol	C₁₅H₂₂O₃	MeOH	Rhizomes	[25]
145	Calamensesquiterpinenol	C₁₅H₂₄O₂	MeOH	Rhizomes	[25]
146	2,3,3a,7,8,8a-hexahydro-3a-hydroxy-1,4-dimethyl- 7-(1-methylethylidene)- 6(1H)-azulenone	C₁₅H₂₂O₂	MeOH	Rhizomes	[25]
147	2-acetoxyacorenone	C₁₇H₂₆O₃	MeOH	Rhizomes	[25]
148	Aspidinol	C₁₂H₁₆O₄	95% EtOH	Rhizomes	[1]
149	Apocynin	C₉H₁₀O₃	95% EtOH	Rhizomes	[1]
150	Aeru-gidiol	C₁₅H₂₂O₃	95% EtOH	Rhizomes	[1]
151	Ethanone	C₁₁H₁₄O₄	95% EtOH	Rhizomes	[1]
152	3-butyl-phthalide	C₁₂H₁₄O₂	95% EtOH	Rhizomes	[1]
153	Asaraldehyde	C₁₀H₁₂O₄	95% EtOH	Rhizomes	[1]
154	Cala-musenone	C₁₅H₂₂O	95% EtOH	Rhizomes	[1]
155	Zederone	C₁₅H₁₈O₃	95% EtOH	Rhizomes	[1]
156	Bisasaricin	C₂₄H₃₂O₆	95% EtOH	Rhizomes	[1]
157	3,4,5-trimethoxytoluene	C₁₀H₁₄O₃	95% EtOH	Rhizomes	[1]
158	1-(2,4,5-trimethoxyphenyl)-1,2-propanediol	C₁₂H₁₈O₅	95% EtOH	Rhizomes	[1]
159	Calamendiol	C₁₅H₂₆O₂	95% EtOH	Rhizomes	[1]
160	α-calacorene	C₁₅H₂₀	95% EtOH	Rhizomes	[1]
161	Acotatarone C	C₁₅H₂₂O₂	95% EtOH	Rhizomes	[1]
162	Cyperol	C₁₅H₂₄O	95% EtOH	Rhizomes	[1]
163	Diisocapryl phthalate	C₂₄H₃₈O₄	95% EtOH	Rhizomes	[1]
164	Labetalol	C₁₉H₂₄N₂O₃	95% EtOH	Rhizomes	[1]

Table 2

Summary of pharmacological activities of A. tatarinowii extracts/compounds.

Pharmacological Activities	Study Design	Models	Results/Mechanisms	Dosages	Reference
Antidepressant	In vivo	Male C57/BL6 mice	↑SERT activity↓SERT activity	1.56 μg/mL50–100 μg/mL	[9]
	In vivo	Male ICR mice	Significantly reduced immobility time	5, 10, and 20 mg/kg	[46]
	In vivo	CUMS rats	Significantly reduced immobility time, reduced the level of sucrose preference, and increased the CREB and BDNF mRNA levels	25 mg/kg	[47]
Antiepileptic	In vivo	Kunming mice and male SD rats	↓GABA-IR neuron damage	100 mg/kg	[48]
Anticonvulsant	In vivo	Male ICR mice or SD rats	Up-regulation of GABA_A and GAD65expressions and anti-apoptosis of neurons in the brain	5, 10, and 20 mg/kg	[49]
	In vivo	The pain models in mice	Regulate GABA activity	100 and 200 mg/kg	[50]
Antianxiety	In vivo	Mice (chronic inflammatory mouse model)	Blocked CFA-induced anxiety-like behavior, regulating the balance between GABAergic and glutamatergic transmission in the basolateral (BLA)	20 mg/kg	[51]
Neuroprotective	In vitro	SD rats in cultured astrocytes	The tBHP-induced cell mortality in cultured astrocytes was markedly reduced	0.5–15 μg/mL	[52]
	In vivo	Both SD developmental rat pups and adult rats	Pb-induced reduction of spine density in hippocampal CA1 and effectively up-regulated the protein expression of NR2B, Arc, and Wnt7a, as well as the mRNA levels of Arc/Arg3.1 and Wnt7a	(10, 40 mg/kg) and (2.5, 10, 40 mg/kg)	[12]
Protective effects against Alzheimer’s disease	In vitro	PC12 cell	Inhibits Amyloid-β	12, 24, 36, 72, and 144 μM	[53]
	In vivo	Male Wistar rats	Significantly increased the levels of antioxidant enzymes, including SOD and GPX	12.5, 25, and 50 mg/kg	[54]
Antifatigue	In vivo	Adult male SD rats	Suppress the exercise-induced increase in 5-HT synthesis, TPH2 mRNA, and protein expression and preventthe exercise-induced decrease in 5-HT1B mRNA and protein expression in the dorsal raphe	100 mg/kg	[55]
Antifungal	In vivo and in vitro	Six-week-old female Kunming mice and C. albicans strain	Inhibiting the activity of C. albicans and inhibit biofilm formation by regulating the C. albicans protein kinase C pathway.	8 mg/kg	[1]

“↑” indicates a upward revision; “↓” indicates a downward revision.

References

1. Wang, Z.J.; Zhu, Y.Y.; Yi, X.; Zhou, Z.S.; He, Y.J.; Zhou, Y.; Qi, Z.H.; Jin, D.N.; Zhao, L.X.; Luo, X.D. Bioguided isolation, identification and activity evaluation of antifungal compounds from Acorus tatarinowii Schott. J. Ethnopharmacol.; 2020; 261, 113119. [DOI: https://dx.doi.org/10.1016/j.jep.2020.113119] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32679258]

2. Cheng, Z.; Shu, H.; Zhang, S.; Luo, B.; Gu, R.; Zhang, R.; Ji, Y.; Li, F.; Long, C. From Folk Taxonomy to Species Confirmation of Acorus (Acoraceae): Evidences Based on Phylogenetic and Metabolomic Analyses. Front. Plant Sci.; 2020; 11, 965. [DOI: https://dx.doi.org/10.3389/fpls.2020.00965] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32670345]

3. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China; 2nd ed. China Medical Science Press: Beijing, China, 1963.

4. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China; 11th ed. China Medical Science Press: Beijing, China, 2020.

5. Lee, Y.C.; Kao, S.T.; Cheng, C.Y. Acorus tatarinowii Schott extract reduces cerebral edema caused by ischemia-reperfusion injury in rats: Involvement in regulation of astrocytic NKCC1/AQP4 and JNK/iNOS-mediated signaling. BMC Complement. Med. Ther.; 2020; 20, 374. [DOI: https://dx.doi.org/10.1186/s12906-020-03168-z] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33298024]

6. Li, J.M.; Zhao, Y.; Sun, Y.; Kong, L.D. Potential effect of herbal antidepressants on cognitive deficit: Pharmacological activity and possible molecular mechanism. J. Ethnopharmacol.; 2020; 257, 112830. [DOI: https://dx.doi.org/10.1016/j.jep.2020.112830]

7. Chellian, R.; Pandy, V.; Mohamed, Z. Pharmacology and toxicology of α- and β-Asarone: A review of preclinical evidence. Phytomedicine; 2017; 32, pp. 41-58. [DOI: https://dx.doi.org/10.1016/j.phymed.2017.04.003]

8. Lam, K.Y.C.; Wu, Q.Y.; Hu, W.H.; Yao, P.; Wang, H.Y.; Dong, T.T.X.; Tsim, K.W.K. Asarones from Acori Tatarinowii Rhizoma stimulate expression and secretion of neurotrophic factors in cultured astrocytes. Neurosci. Lett.; 2019; 707, 134308. [DOI: https://dx.doi.org/10.1016/j.neulet.2019.134308]

9. Zhang, F.H.; Wang, Z.M.; Liu, Y.T.; Huang, J.S.; Liang, S.; Wu, H.H.; Xu, Y.T. Bioactivities of serotonin transporter mediate antidepressant effects of Acorus tatarinowii Schott. J. Ethnopharmacol.; 2019; 241, 111967. [DOI: https://dx.doi.org/10.1016/j.jep.2019.111967]

10. Jaiswal, Y.; Liang, Z.; Ho, A.; Chen, H.; Zhao, Z. Metabolite profiling of tissues of Acorus calamus and Acorus tatarinowii rhizomes by using LMD, UHPLC-QTOF MS, and GC-MS. Planta Med.; 2015; 81, pp. 333-341. [DOI: https://dx.doi.org/10.1055/s-0035-1545694]

11. Unger, P.; Melzig, M.F. Comparative study of the cytotoxicity and genotoxicity of alpha- and Beta-asarone. Sci. Pharm.; 2012; 80, pp. 663-668. [DOI: https://dx.doi.org/10.3797/scipharm.1204-21]

12. Yang, Q.Q.; Xue, W.Z.; Zou, R.X.; Xu, Y.; Du, Y.; Wang, S.; Xu, L.; Chen, Y.Z.; Wang, H.L.; Chen, X.T. β-Asarone Rescues Pb-Induced Impairments of Spatial Memory and Synaptogenesis in Rats. PLoS ONE; 2016; 11, e0167401. [DOI: https://dx.doi.org/10.1371/journal.pone.0167401]

13. Zhong, R.N.; Wang, X.H.; Wan, L.; Shen, C.Y.; Shen, B.D.; Wang, J.; Han, L.; Yuan, H.L. [Study on preparation of volatile oil from Acorus tatarinowii self-nanoemulsion dropping pills and its protective effect on acute myocardial ischemia injury]. Zhongguo Zhong Yao Za Zhi; 2019; 44, pp. 1357-1362. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31090292]

14. Lam, K.Y.; Ku, C.F.; Wang, H.Y.; Chan, G.K.; Yao, P.; Lin, H.Q.; Dong, T.T.; Zhang, H.J.; Tsim, K.W. Authentication of Acori Tatarinowii Rhizoma (Shi Chang Pu) and its adulterants by morphological distinction, chemical composition and ITS sequencing. Chin. Med.; 2016; 11, 41. [DOI: https://dx.doi.org/10.1186/s13020-016-0113-x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27708691]

15. Zhu, K.Y.; Xu, S.L.; Choi, R.C.; Yan, A.L.; Dong, T.T.; Tsim, K.W. Kai-xin-san, a chinese herbal decoction containing ginseng radix et rhizoma, polygalae radix, acori tatarinowii rhizoma, and poria, stimulates the expression and secretion of neurotrophic factors in cultured astrocytes. Evid. Based Complement. Alternat. Med.; 2013; 2013, 731385. [DOI: https://dx.doi.org/10.1155/2013/731385] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24222781]

16. Huang, S.J.; Zhang, X.H.; Wang, Y.Y.; Pan, J.H.; Cui, H.M.; Fang, S.P.; Wu, W.; Zheng, J.; Li, D.J.; Bai, G. Effects of Kaixin Jieyu Decoction () on behavior, monoamine neurotransmitter levels, and serotonin receptor subtype expression in the brain of a rat depression model. Chin. J. Integr. Med.; 2014; 20, pp. 280-285. [DOI: https://dx.doi.org/10.1007/s11655-014-1343-0] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24567255]

17. Yan, L.; Xu, S.L.; Zhu, K.Y.; Lam, K.Y.; Xin, G.; Maiwulanjiang, M.; Li, N.; Dong, T.T.; Lin, H.; Tsim, K.W. Optimizing the compatibility of paired-herb in an ancient Chinese herbal decoction Kai-Xin-San in activating neurofilament expression in cultured PC12 cells. J. Ethnopharmacol.; 2015; 162, pp. 155-162. [DOI: https://dx.doi.org/10.1016/j.jep.2014.12.049]

18. Wang, Q.; Yuan, L.L.; Zhang, Y.L.; Fan, W.T. [Research on network pharmacology of Acori Tatarinowii Rhizoma combined with Curcumae Radix in treating epilepsy]. Zhongguo Zhong Yao Za Zhi; 2019; 44, pp. 2701-2708.

19. Xiong, W.; Zhao, X.; Xu, Q.; Wei, G.; Zhang, L.; Fan, Y.; Wen, L.; Liu, Y.; Zhang, T.; Zhang, L. et al. Qisheng Wan formula ameliorates cognitive impairment of Alzheimer’s disease rat via inflammation inhibition and intestinal microbiota regulation. J. Ethnopharmacol.; 2022; 282, 114598. [DOI: https://dx.doi.org/10.1016/j.jep.2021.114598]

20. Dang, H.; Sun, L.; Liu, X.; Peng, B.; Wang, Q.; Jia, W.; Chen, Y.; Pan, A.; Xiao, P. Preventive action of Kai Xin San aqueous extract on depressive-like symptoms and cognition deficit induced by chronic mild stress. Exp. Biol. Med.; 2009; 234, pp. 785-793. [DOI: https://dx.doi.org/10.3181/0812-RM-354]

21. Huang, Z.; Mao, Q.Q.; Zhong, X.M.; Feng, C.R.; Pan, A.J.; Li, Z.Y. Herbal formula SYJN protect PC12 cells from neurotoxicity induced by corticosterone. J. Ethnopharmacol.; 2009; 125, pp. 456-460. [DOI: https://dx.doi.org/10.1016/j.jep.2009.07.018]

22. Parés-Badell, O.; Barbaglia, G.; Jerinic, P.; Gustavsson, A.; Salvador-Carulla, L.; Alonso, J. Cost of disorders of the brain in Spain. PLoS ONE; 2014; 9, e105471. [DOI: https://dx.doi.org/10.1371/journal.pone.0105471]

23. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol.; 2019; 18, pp. 459-480. [DOI: https://dx.doi.org/10.1016/S1474-4422(18)30499-X] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30879893]

24. Kim, C.J.; Kwak, T.Y.; Bae, M.H.; Shin, H.K.; Choi, B.T. Therapeutic Potential of Active Components from Acorus gramineus and Acorus tatarinowii in Neurological Disorders and Their Application in Korean Medicine. J. Pharmacopunct.; 2022; 25, pp. 326-343. [DOI: https://dx.doi.org/10.3831/KPI.2022.25.4.326] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36628348]

25. Zhang, F.; Qi, P.; Xue, R.; Li, Z.; Zhu, K.; Wan, P.; Huang, C. Qualitative and quantitative analysis of the major constituents in Acorus tatarinowii Schott by HPLC/ESI-QTOF-MS/MS. Biomed. Chromatogr.; 2015; 29, pp. 890-901. [DOI: https://dx.doi.org/10.1002/bmc.3371] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25354491]

26. Wang, Z.; Wang, Q.; Yang, B.; Li, J.; Yang, C.; Meng, Y.; Kuang, H. GC-MS method for determination and pharmacokinetic study of four phenylpropanoids in rat plasma after oral administration of the essential oil of Acorus tatarinowii Schott rhizomes. J. Ethnopharmacol.; 2014; 155, pp. 1134-1140. [DOI: https://dx.doi.org/10.1016/j.jep.2014.06.035]

27. Liang, S.; Ying, S.S.; Wu, H.H.; Liu, Y.T.; Dong, P.Z.; Zhu, Y.; Xu, Y.T. A novel sesquiterpene and three new phenolic compounds from the rhizomes of Acorus tatarinowii Schott. Bioorg. Med. Chem. Lett.; 2015; 25, pp. 4214-4218. [DOI: https://dx.doi.org/10.1016/j.bmcl.2015.08.001]

28. Gao, E.; Zhou, Z.Q.; Zou, J.; Yu, Y.; Feng, X.L.; Chen, G.D.; He, R.R.; Yao, X.S.; Gao, H. Bioactive Asarone-Derived Phenylpropanoids from the Rhizome of Acorus tatarinowii Schott. J. Nat. Prod.; 2017; 80, pp. 2923-2929. [DOI: https://dx.doi.org/10.1021/acs.jnatprod.7b00457]

29. Tong, X.G.; Qiu, B.; Luo, G.F.; Zhang, X.F.; Cheng, Y.X. Alkaloids and sesquiterpenoids from Acorus tatarinowii. J. Asian Nat. Prod. Res.; 2010; 12, pp. 438-442. [DOI: https://dx.doi.org/10.1080/10286020.2010.490522]

30. Ni, G.; Shi, G.R.; Zhang, D.; Fu, N.J.; Yang, H.Z.; Chen, X.G.; Yu, D.Q. Cytotoxic Lignans and Sesquiterpenoids from the Rhizomes of Acorus tatarinowii. Planta Med.; 2016; 82, pp. 632-638. [DOI: https://dx.doi.org/10.1055/s-0035-1568248]

31. Dong, W.; Yang, D.; Lu, R. Chemical constituents from the rhizome of Acorus calamus L. Planta Med.; 2010; 76, pp. 454-457. [DOI: https://dx.doi.org/10.1055/s-0029-1186217]

32. Tong, X.G.; Wu, G.S.; Huang, C.G.; Lu, Q.; Wang, Y.H.; Long, C.L.; Luo, H.R.; Zhu, H.J.; Cheng, Y.X. Compounds from Acorus tatarinowii: Determination of absolute configuration by quantum computations and cAMP regulation activity. J. Nat. Prod.; 2010; 73, pp. 1160-1163. [DOI: https://dx.doi.org/10.1021/np900793e]

33. Hao, Z.Y.; Liang, D.; Luo, H.; Liu, Y.F.; Ni, G.; Zhang, Q.J.; Li, L.; Si, Y.K.; Sun, H.; Chen, R.Y. et al. Bioactive sesquiterpenoids from the rhizomes of Acorus calamus. J. Nat. Prod.; 2012; 75, pp. 1083-1089. [DOI: https://dx.doi.org/10.1021/np300095c] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22671987]

34. Li, J.; Zhao, J.; Wang, W.; Li, L.; Zhang, L.; Zhao, X.F.; Liu, Q.R.; Liu, F.; Yang, M.; Khan, I.A. et al. New Acorane-Type Sesquiterpene from Acorus calamus L. Molecules; 2017; 22, 529. [DOI: https://dx.doi.org/10.3390/molecules22040529] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28346359]

35. Lu, Y.; Xue, Y.; Chen, S.; Zhu, H.; Zhang, J.; Li, X.N.; Wang, J.; Liu, J.; Qi, C.; Du, G. et al. Antioxidant Lignans and Neolignans from Acorus tatarinowii. Sci. Rep.; 2016; 6, 22909. [DOI: https://dx.doi.org/10.1038/srep22909] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26961724]

36. Lu, Y.; Xue, Y.; Liu, J.; Yao, G.; Li, D.; Sun, B.; Zhang, J.; Liu, Y.; Qi, C.; Xiang, M. et al. (±)-Acortatarinowins A-F, Norlignan, Neolignan, and Lignan Enantiomers from Acorus tatarinowii. J. Nat. Prod.; 2015; 78, pp. 2205-2214. [DOI: https://dx.doi.org/10.1021/acs.jnatprod.5b00328] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26305406]

37. Xu, X.; Liu, N.; Wang, Y.; Pan, L.C.; Wu, D.; Peng, Q.; Zhang, M.; Wang, H.B.; Sun, W.C. Tatarinan O, a lignin-like compound from the roots of Acorus tatarinowii Schott inhibits osteoclast differentiation through suppressing the expression of c-Fos and NFATc1. Int. Immunopharmacol.; 2016; 34, pp. 212-219. [DOI: https://dx.doi.org/10.1016/j.intimp.2016.03.001]

38. Ni, G.; Shen, Z.F.; Lu, Y.; Wang, Y.H.; Tang, Y.B.; Chen, R.Y.; Hao, Z.Y.; Yu, D.Q. Glucokinase-activating sesquinlignans from the rhizomes of Acorus tatarinowii Schott. J. Org. Chem.; 2011; 76, pp. 2056-2061. [DOI: https://dx.doi.org/10.1021/jo1022712]

39. Zhang, W.Y.; Feng, X.L.; Lu, D.; Gao, H.; Yu, Y.; Yao, X.S. New lignans attenuating cognitive deterioration of Aβ transgenic flies discovered in Acorus tatarinowii. Bioorg. Med. Chem. Lett.; 2018; 28, pp. 814-819. [DOI: https://dx.doi.org/10.1016/j.bmcl.2017.08.015]

40. Luo, X.H.; Zhang, Y.Y.; Chen, X.Y.; Sun, M.L.; Li, S.; Wang, H.B. Lignans from the roots of Acorus tatarinowii Schott ameliorate β amyloid-induced toxicity in transgenic Caenorhabditis elegans. Fitoterapia; 2016; 108, pp. 5-8. [DOI: https://dx.doi.org/10.1016/j.fitote.2015.11.010]

41. Feng, X.L.; Li, H.B.; Gao, H.; Huang, Y.; Zhou, W.X.; Yu, Y.; Yao, X.S. Bioactive Nitrogenous Compounds from Acorus tatarinowii. Magn. Reson. Chem.; 2016; 54, pp. 396-399. [DOI: https://dx.doi.org/10.1002/mrc.4393]

42. Li, J.; Li, Z.X.; Zhao, J.P.; Wang, W.; Zhao, X.F.; Xu, B.; Li, L.; Zhang, L.; Ren, J.; Khan, I.A. et al. A Novel Tropoloisoquinoline Alkaloid, Neotatarine, from Acorus calamus L. Chem. Biodivers.; 2017; 14, e1700201. [DOI: https://dx.doi.org/10.1002/cbdv.201700201]

43. Tong, X.G.; Zhou, L.L.; Wang, Y.H.; Xia, C.; Wang, Y.; Liang, M.; Hou, F.F.; Cheng, Y.X. Acortatarins A and B, two novel antioxidative spiroalkaloids with a naturally unusual morpholine motif from Acorus tatarinowii. Org. Lett.; 2010; 12, pp. 1844-1847. [DOI: https://dx.doi.org/10.1021/ol100451p] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20329735]

44. Yang, K.; Qiu, J.; Huang, Z.; Yu, Z.; Wang, W.; Hu, H.; You, Y. A comprehensive review of ethnopharmacology, phytochemistry, pharmacology, and pharmacokinetics of Schisandra chinensis (Turcz.) Baill. and Schisandra sphenanthera Rehd. et Wils. J. Ethnopharmacol.; 2022; 284, 114759. [DOI: https://dx.doi.org/10.1016/j.jep.2021.114759] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34678416]

45. Jiang, H.; Yang, L.; Hou, A.; Zhang, J.; Wang, S.; Man, W.; Zheng, S.; Yu, H.; Wang, X.; Yang, B. et al. Botany, traditional uses, phytochemistry, analytical methods, processing, pharmacology and pharmacokinetics of Bupleuri Radix: A systematic review. Biomed. Pharmacother.; 2020; 131, 110679. [DOI: https://dx.doi.org/10.1016/j.biopha.2020.110679]

46. Han, P.; Han, T.; Peng, W.; Wang, X.R. Antidepressant-like effects of essential oil and asarone, a major essential oil component from the rhizome of Acorus tatarinowii. Pharm. Biol.; 2013; 51, pp. 589-594. [DOI: https://dx.doi.org/10.3109/13880209.2012.751616] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23363070]

47. Dong, H.; Gao, Z.; Rong, H.; Jin, M.; Zhang, X. β-asarone reverses chronic unpredictable mild stress-induced depression-like bhavior and promotes hippocampal neurogenesis in rats. Molecules; 2014; 19, pp. 5634-5649. [DOI: https://dx.doi.org/10.3390/molecules19055634]

48. Liao, W.P.; Chen, L.; Yi, Y.H.; Sun, W.W.; Gao, M.M.; Su, T.; Yang, S.Q. Study of antiepileptic effect of extracts from Acorus tatarinowii Schott. Epilepsia; 2005; 46, pp. 21-24. [DOI: https://dx.doi.org/10.1111/j.0013-9580.2005.461007.x]

49. Liu, H.; Song, Z.; Liao, D.G.; Zhang, T.Y.; Liu, F.; Zhuang, K.; Luo, K.; Yang, L.; He, J.; Lei, J.P. Anticonvulsant and Sedative Effects of Eudesmin isolated from Acorus tatarinowii on mice and rats. Phytother. Res.; 2015; 29, pp. 996-1003. [DOI: https://dx.doi.org/10.1002/ptr.5337]

50. Rajput, S.B.; Tonge, M.B.; Karuppayil, S.M. An overview on traditional uses and pharmacological profile of Acorus calamus Linn. (Sweet flag) and other Acorus species. Phytomedicine; 2014; 21, pp. 268-276. [DOI: https://dx.doi.org/10.1016/j.phymed.2013.09.020]

51. Tian, J.; Tian, Z.; Qin, S.L.; Zhao, P.Y.; Jiang, X.; Tian, Z. Anxiolytic-like effects of α-asarone in a mouse model of chronic pain. Metab. Brain Dis.; 2017; 32, pp. 2119-2129. [DOI: https://dx.doi.org/10.1007/s11011-017-0108-z]

52. Lam, K.Y.C.; Yao, P.; Wang, H.; Duan, R.; Dong, T.T.X.; Tsim, K.W.K. Asarone from Acori Tatarinowii Rhizome prevents oxidative stress-induced cell injury in cultured astrocytes: A signaling triggered by Akt activation. PLoS ONE; 2017; 12, e0179077. [DOI: https://dx.doi.org/10.1371/journal.pone.0179077]

53. Wang, N.; Wang, H.; Li, L.; Li, Y.; Zhang, R. β-Asarone Inhibits Amyloid-β by Promoting Autophagy in a Cell Model of Alzheimer’s Disease. Front. Pharmacol.; 2020; 10, 1529. [DOI: https://dx.doi.org/10.3389/fphar.2019.01529] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32009952]

54. Saki, G.; Eidi, A.; Mortazavi, P.; Panahi, N.; Vahdati, A. Effect of β-asarone in normal and β-amyloid-induced Alzheimeric rats. Arch. Med. Sci.; 2020; 16, pp. 699-706. [DOI: https://dx.doi.org/10.5114/aoms.2020.94659] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32399120]

55. Zhu, M.; Zhu, H.; Tan, N.; Zeng, G.; Zeng, Z.; Chu, H.; Wang, H.; Xia, Z.; Wu, R. The effects of Acorus tatarinowii Schott on 5-HT concentrations, TPH2 and 5-HT1B expression in the dorsal raphe of exercised rats. J. Ethnopharmacol.; 2014; 158, pp. 431-436. [DOI: https://dx.doi.org/10.1016/j.jep.2014.10.026]

56. Zhang, Y.; Long, Y.; Yu, S.; Li, D.; Yang, M.; Guan, Y.; Zhang, D.; Wan, J.; Liu, S.; Shi, A. et al. Natural volatile oils derived from herbal medicines: A promising therapy way for treating depressive disorder. Pharmacol. Res.; 2021; 164, 105376. [DOI: https://dx.doi.org/10.1016/j.phrs.2020.105376] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33316383]

57. Charlson, F.J.; Baxter, A.J.; Cheng, H.G.; Shidhaye, R.; Whiteford, H.A. The burden of mental, neurological, and substance use disorders in China and India: A systematic analysis of community representative epidemiological studies. Lancet; 2016; 388, pp. 376-389. [DOI: https://dx.doi.org/10.1016/S0140-6736(16)30590-6]

58. Ding, D.; Zhou, D.; Sander, J.W.; Wang, W.; Li, S.; Hong, Z. Epilepsy in China: Major progress in the past two decades. Lancet Neurol.; 2021; 20, pp. 316-326. [DOI: https://dx.doi.org/10.1016/S1474-4422(21)00023-5]

59. Nandakumar, S.; Menon, S.; Shailajan, S. A rapid HPLC-ESI-MS/MS method for determination of β-asarone, a potential anti-epileptic agent, in plasma after oral administration of Acorus calamus extract to rats. Biomed. Chromatogr.; 2013; 27, pp. 318-326. [DOI: https://dx.doi.org/10.1002/bmc.2794]

60. Huang, C.; Li, W.G.; Zhang, X.B.; Wang, L.; Xu, T.L.; Wu, D.; Li, Y. α-asarone from Acorus gramineus alleviates epilepsy by modulating A-type GABA receptors. Neuropharmacology; 2013; 65, pp. 1-11. [DOI: https://dx.doi.org/10.1016/j.neuropharm.2012.09.001]

61. Zhao, X.; Liang, L.; Xu, R.; Cheng, P.; Jia, P.; Bai, Y.; Zhang, Y.; Zhao, X.; Zheng, X.; Xiao, C. Revealing the Antiepileptic Effect of α-Asaronol on Pentylenetetrazole-Induced Seizure Rats Using NMR-Based Metabolomics. ACS Omega; 2022; 7, pp. 6322-6334. [DOI: https://dx.doi.org/10.1021/acsomega.1c06922]

62. Chin, R.F.; Neville, B.G.; Peckham, C.; Bedford, H.; Wade, A.; Scott, R.C. NLSTEPSS Collaborative Group. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: Prospective population-based study. Lancet; 2006; 368, pp. 222-229. [DOI: https://dx.doi.org/10.1016/S0140-6736(06)69043-0]

63. Sánchez Fernández, I.; Goodkin, H.P.; Scott, R.C. Pathophysiology of convulsive status epilepticus. Seizure; 2019; 68, pp. 16-21. [DOI: https://dx.doi.org/10.1016/j.seizure.2018.08.002] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30170734]

64. Chen, Q.X.; Miao, J.K.; Li, C.; Li, X.W.; Wu, X.M.; Zhang, X.P. Anticonvulsant activity of acute and chronic treatment with a-asarone from Acorus gramineus in seizure models. Biol. Pharm. Bull.; 2013; 36, pp. 23-30. [DOI: https://dx.doi.org/10.1248/bpb.b12-00376] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23075695]

65. Colla, A.R.; Rosa, J.M.; Cunha, M.P.; Rodrigues, A.L. Anxiolytic-like effects of ursolic acid in mice. Eur. J. Pharmacol.; 2015; 758, pp. 171-176. [DOI: https://dx.doi.org/10.1016/j.ejphar.2015.03.077] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25861934]

66. Koga, K.; Descalzi, G.; Chen, T.; Ko, H.G.; Lu, J.; Li, S.; Son, J.; Kim, T.; Kwak, C.; Huganir, R.L. et al. Coexistence of two forms of LTP in ACC provides a synaptic mechanism for the interactions between anxiety and chronic pain. Neuron; 2015; 85, pp. 377-389. [DOI: https://dx.doi.org/10.1016/j.neuron.2014.12.021]

67. Wang, G.Q.; Cen, C.; Li, C.; Cao, S.; Wang, N.; Zhou, Z.; Liu, X.M.; Xu, Y.; Tian, N.X.; Zhang, Y. et al. Deactivation of excitatory neurons in the prelimbic cortex via Cdk5 promotes pain sensation and anxiety. Nat. Commun.; 2015; 6, 7660. [DOI: https://dx.doi.org/10.1038/ncomms8660]

68. Olsen, R.W.; Sieghart, W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: Classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev.; 2008; 60, pp. 243-260. [DOI: https://dx.doi.org/10.1124/pr.108.00505]

69. Tian, Z.; Wang, Y.; Zhang, N.; Guo, Y.Y.; Feng, B.; Liu, S.B.; Zhao, M.G. Estrogen receptor GPR30 exerts anxiolytic effects by maintaining the balance between GABAergic and glutamatergic transmission in the basolateral amygdala of ovariectomized mice after stress. Psychoneuroendocrinology; 2013; 38, pp. 2218-2233. [DOI: https://dx.doi.org/10.1016/j.psyneuen.2013.04.011]

70. Yan, L.; Mahady, G.; Qian, Y.; Song, P.; Jian, T.; Ding, X.; Guan, F.; Shan, Y.; Wei, M. The Essential Oil from Acori Tatarinowii Rhizome (the Dried Rhizome of Acorus tatarinowii Schott) Prevents Hydrogen Peroxide-Induced Cell Injury in PC12 Cells: A Signaling Triggered by CREB/PGC-1α Activation. Evid. Based Complement. Alternat. Med.; 2020; 2020, 4845028. [DOI: https://dx.doi.org/10.1155/2020/4845028]

71. Manikandan, S.; Srikumar, R.; Jeya Parthasarathy, N.; Sheela Devi, R. Protective effect of Acorus calamus LINN on free radical scavengers and lipid peroxidation in discrete regions of brain against noise stress exposed rat. Biol. Pharm. Bull.; 2005; 28, pp. 2327-2330. [DOI: https://dx.doi.org/10.1248/bpb.28.2327]

72. Yang, Y.X.; Chen, Y.T.; Zhou, X.J.; Hong, C.L.; Li, C.Y.; Guo, J.Y. Beta-asarone, a major component of Acorus tatarinowii Schott, attenuates focal cerebral ischemia induced by middle cerebral artery occlusion in rats. BMC Complement. Altern. Med.; 2013; 13, 236. [DOI: https://dx.doi.org/10.1186/1472-6882-13-236]

73. Lam, K.Y.; Chen, J.; Lam, C.T.; Wu, Q.; Yao, P.; Dong, T.T.; Lin, H.; Tsim, K.W. Asarone from Acori Tatarinowii Rhizoma Potentiates the Nerve Growth Factor-Induced Neuronal Differentiation in Cultured PC12 Cells: A Signaling Mediated by Protein Kinase, A. PLoS ONE; 2016; 11, e0163337. [DOI: https://dx.doi.org/10.1371/journal.pone.0163337] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27685847]

74. Balakrishnan, R.; Cho, D.Y.; Kim, I.S.; Seol, S.H.; Choi, D.K. Molecular Mechanisms and Therapeutic Potential of α- and β-Asarone in the Treatment of Neurological Disorders. Antioxidants; 2022; 11, 281. [DOI: https://dx.doi.org/10.3390/antiox11020281] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35204164]

75. Kumar, H.; Kim, B.W.; Song, S.Y.; Kim, J.S.; Kim, I.S.; Kwon, Y.S.; Koppula, S.; Choi, D.K. Cognitive enhancing effects of alpha asarone in amnesic mice by influencing cholinergic and antioxidant defense mechanisms. Biosci. Biotechnol. Biochem.; 2012; 76, pp. 1518-1522. [DOI: https://dx.doi.org/10.1271/bbb.120247] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22878197]

76. Xu, F.; Wu, H.; Zhang, K.; Lv, P.; Zheng, L.; Zhao, J. Pro-neurogenic effect of β-asarone on RSC96 Schwann cells in vitro. In Vitro Cell. Dev. Biol. Anim.; 2016; 52, pp. 278-286. [DOI: https://dx.doi.org/10.1007/s11626-015-9980-1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26659394]

77. Zhang, W.; Song, D.; Xu, D.; Wang, T.; Chen, L.; Duan, J. Characterization of polysaccharides with antioxidant and immunological activities from Rhizoma Acori Tatarinowii. Carbohydr. Polym.; 2015; 133, pp. 154-162. [DOI: https://dx.doi.org/10.1016/j.carbpol.2015.07.018]

78. Wang, D.; Wang, X.; Li, X.; Ye, L. Preparation and characterization of solid lipid nanoparticles loaded with alpha-Asarone. PDA J. Pharm. Sci. Technol.; 2008; 62, pp. 56-65.

79. Hu, Y.; Yuan, M.; Liu, P.; Mu, L.; Wang, H. [Effect of Acorus tatarinowii schott on ultrastructure and permeability of blood-brain barrier]. Zhongguo Zhong Yao Za Zhi; 2009; 34, pp. 349-351.

80. Ferreira-Vieira, T.H.; Guimaraes, I.M.; Silva, F.R.; Ribeiro, F.M. Alzheimer’s disease: Targeting the Cholinergic System. Curr. Neuropharmacol.; 2016; 14, pp. 101-115. [DOI: https://dx.doi.org/10.2174/1570159X13666150716165726]

81. Mendelsohn, A.R.; Larrick, J.W. Cellular Senescence as the Key Intermediate in Tau-Mediated Neurodegeneration. Rejuvenation Res.; 2018; 21, pp. 572-579. [DOI: https://dx.doi.org/10.1089/rej.2018.2155]

82. Wang, S.; Jiang, W.; Ouyang, T.; Shen, X.Y.; Wang, F.; Qu, Y.H.; Zhang, M.; Luo, T.; Wang, H.Q. Jatrorrhizine Balances the Gut Microbiota and Reverses Learning and Memory Deficits in APP/PS1 transgenic mice. Sci. Rep.; 2019; 9, 19575. [DOI: https://dx.doi.org/10.1038/s41598-019-56149-9]

83. Yang, Y.; Xuan, L.; Chen, H.; Dai, S.; Ji, L.; Bao, Y.; Li, C. Neuroprotective Effects and Mechanism of β-Asarone against Aβ1-42-Induced Injury in Astrocytes. Evid. Based Complement. Alternat. Med.; 2017; 2017, 8516518. [DOI: https://dx.doi.org/10.1155/2017/8516518] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29599803]

84. Li, C.; Xing, G.; Dong, M.; Zhou, L.; Li, J.; Wang, G.; Zou, D.; Wang, R.; Liu, J.; Niu, Y. Beta-asarone protection against beta-amyloid-induced neurotoxicity in PC12 cells via JNK signaling and modulation of Bcl-2 family proteins. Eur. J. Pharmacol.; 2010; 635, pp. 96-102. [DOI: https://dx.doi.org/10.1016/j.ejphar.2010.03.013] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20307525]

85. Mo, Z.T.; Fang, Y.Q.; He, Y.P.; Zhang, S. β-Asarone protects PC12 cells against OGD/R-induced injury via attenuating Beclin-1-dependent autophagy. Acta Pharmacol. Sin.; 2012; 33, pp. 737-742. [DOI: https://dx.doi.org/10.1038/aps.2012.35] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22543703]

86. An, H.M.; Li, G.W.; Lin, C.; Gu, C.; Jin, M.; Sun, W.X.; Qiu, M.F.; Hu, B. Acorus tatarinowii Schott extract protects PC12 cells from amyloid-beta induced neurotoxicity. Pharmazie; 2014; 69, pp. 391-395.

87. Wang, N.; Wang, H.; Pan, Q.; Kang, J.; Liang, Z.; Zhang, R. The Combination of β-Asarone and Icariin Inhibits Amyloid-β and Reverses Cognitive Deficits by Promoting Mitophagy in Models of Alzheimer’s Disease. Oxid. Med. Cell. Longev.; 2021; 2021, 7158444. [DOI: https://dx.doi.org/10.1155/2021/7158444]

88. Liu, J.; Li, C.; Xing, G.; Zhou, L.; Dong, M.; Geng, Y.; Li, X.; Li, J.; Wang, G.; Zou, D. et al. Beta-asarone attenuates neuronal apoptosis induced by Beta amyloid in rat hippocampus. Yakugaku Zasshi; 2010; 130, pp. 737-746. [DOI: https://dx.doi.org/10.1248/yakushi.130.737]

89. Zou, D.J.; Wang, G.; Liu, J.C.; Dong, M.X.; Li, X.M.; Zhang, C.; Zhou, L.; Wang, R.; Niu, Y.C. Beta-asarone attenuates beta-amyloid-induced apoptosis through the inhibition of the activation of apoptosis signal-regulating kinase 1 in SH-SY5Y cells. Pharmazie; 2011; 66, pp. 44-51.

90. Cotel, F.; Exley, R.; Cragg, S.J.; Perrier, J.F. Serotonin spillover onto the axon initial segment of motoneurons induces central fatigue by inhibiting action potential initiation. Proc. Natl. Acad. Sci. USA; 2013; 110, pp. 4774-4779. [DOI: https://dx.doi.org/10.1073/pnas.1216150110]

91. Twomey, R.; Aboodarda, S.J.; Kruger, R.; Culos-Reed, S.N.; Temesi, J.; Millet, G.Y. Neuromuscular fatigue during exercise: Methodological considerations, etiology and potential role in chronic fatigue. Neurophysiol. Clin.; 2017; 47, pp. 95-110. [DOI: https://dx.doi.org/10.1016/j.neucli.2017.03.002]

92. Zhu, M.J.; Mao, Z.H.; Guo, H.Y.; Zhu, H.Z.; Ding, X.M. [Effects of acorus tatarinowii Schott and alpha asarone on free radicals and nNOS/NO in hippocampus of rats with fatigue movement]. Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2020; 36, pp. 306-311.

93. Pfaller, M.A.; Diekema, D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev.; 2007; 20, pp. 133-163. [DOI: https://dx.doi.org/10.1128/CMR.00029-06] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17223626]

94. Lockhart, S.R.; Guarner, J. Emerging and reemerging fungal infections. Semin. Diagn. Pathol.; 2019; 36, pp. 177-181. [DOI: https://dx.doi.org/10.1053/j.semdp.2019.04.010] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31010605]

95. Srivastava, V.; Singla, R.K.; Dubey, A.K. Emerging Virulence, Drug Resistance and Future Anti-fungal Drugs for Candida Pathogens. Curr. Top. Med. Chem.; 2018; 18, pp. 759-778. [DOI: https://dx.doi.org/10.2174/1568026618666180528121707] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29807516]

96. Lee, Y.; Puumala, E.; Robbins, N.; Cowen, L.E. Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond. Chem. Rev.; 2021; 121, pp. 3390-3411. [DOI: https://dx.doi.org/10.1021/acs.chemrev.0c00199]

97. Wang, Z.; Qiu, Y.; Hou, C.; Wang, D.; Sun, F.; Li, X.; Wang, F.; Yi, H.; Mu, H.; Duan, J. Synthesis of hyaluronan-amikacin conjugate and its bactericidal activity against intracellular bacteria in vitro and in vivo. Carbohydr. Polym.; 2018; 181, pp. 132-140. [DOI: https://dx.doi.org/10.1016/j.carbpol.2017.10.061]

98. Moudgal, V.; Sobel, J. Antifungals to treat Candida albicans. Expert Opin. Pharmacother.; 2010; 11, pp. 2037-2048. [DOI: https://dx.doi.org/10.1517/14656566.2010.493875]

99. Uebel, T.; Hermes, L.; Haupenthal, S.; Müller, L.; Esselen, M. α-Asarone, β-asarone, and γ-asarone: Current status of toxicological evaluation. J. Appl. Toxicol.; 2021; 41, pp. 1166-1179. [DOI: https://dx.doi.org/10.1002/jat.4112]

100. Stegmüller, S.; Schrenk, D.; Cartus, A.T. Formation and fate of DNA adducts of alpha- and beta-asarone in rat hepatocytes. Food Chem. Toxicol.; 2018; 116, pp. 138-146. [DOI: https://dx.doi.org/10.1016/j.fct.2018.04.025]

101. Zhong, R.N.; Wang, X.H.; Wang, X.T.; Shen, B.D.; Shen, C.Y.; Wang, J.; Han, L.; Yuan, H.L. [Preparation and quality evaluation of volatile oil from Acori Tatarinowii Rhizoma self-nanoemulsion]. Zhongguo Zhong Yao Za Zhi; 2018; 43, pp. 4062-4068.

102. Zhang, S.; Zhao, L.; Shan, C.; Shi, Y.; Ma, K.; Wu, J. Exploring the biosynthetic pathway of lignin in Acorus tatarinowii Schott using de novo leaf and rhizome transcriptome analysis. Biosci. Rep.; 2021; 41, 20210006. [DOI: https://dx.doi.org/10.1042/BSR20210006]

Word count: 12657

Show less

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Translate

Acorus tatarinowii Schott (A. tatarinowii) is a natural medicinal plant. It plays an indispensable role in the treatment of diseases by the empirical medicine system and has achieved remarkable curative effects. A. tatarinowii is often used to treat various diseases, such as depression, epilepsy, fever, dizziness, heartache, stomachache, etc. More than 160 compounds of different structural types have been identified in A. tatarinowii, including phenylpropanoids, terpenoids, lignans, flavonoids, alkaloids, amides, and organic acids. These bioactive ingredients make A. tatarinowii remarkable for its pharmacological effects, including antidepressant, antiepileptic, anticonvulsant, antianxiety, neuroprotective, antifatigue, and antifungal effects, improving Alzheimer’s disease, and so on. It is noteworthy that A. tatarinowii has been widely used in the treatment of brain diseases and nervous system diseases and has achieved satisfactory therapeutic effects. This review focused on the research publications of A. tatarinowii and aimed to summarize the advances in the botany, traditional uses, phytochemistry, and pharmacology, which will provide a reference for further studies and applications of A. tatarinowii.

Details

Title

Acorus tatarinowii Schott: A Review of Its Botany, Traditional Uses, Phytochemistry, and Pharmacology

Author

Wang, Meng; Hai-Peng, Tang; Wang, Shuang; Wen-Jing, Hu; Jia-Yan, Li; Ai-Qi, Yu; Qian-Xiang Bai; Bing-You, Yang; Hai-Xue Kuang

First page

4525

Publication year

2023

Publication date

2023

Publisher

MDPI AG

e-ISSN

14203049

Source type

Scholarly Journal

Language of publication

English

DOI

https://doi.org/10.3390/molecules28114525

ProQuest document ID

2824043250

Acorus tatarinowii Schott: A Review of Its Botany, Traditional Uses, Phytochemistry, and Pharmacology

Jump to:

Full Text

Abstract

Details

Suggested sources